activinA对大鼠卵泡发育的调控及分子机制研究
|
摘要
多囊卵巢综合征（polycystic ovary syndrome, PCOS）是临床妇科最常见的内分泌紊乱症候群，也是生育期女性不孕的主要原因。卵泡发育异常是PCOS的病理生理特征之一，目前发病机制不清。有文献报道PCOS患者血清激活素（activins）表达水平降低，而activins可能具有促进颗粒细胞增殖与分化、调控卵泡发育等作用，因此我们推测activins可能在PCOS卵泡发育障碍中发挥重要作用。为明确activins在卵泡发育中的作用及可能的分子机制，我们设计本实验。
第一部分：慢病毒载体（LV-eGFP）转染大鼠卵巢颗粒细胞的体内外实验研究
目的：探讨LV-eGFP体外转染卵巢颗粒细胞的有效性及体内转染大鼠卵巢组织的最佳剂量及时效性。方法：大鼠卵巢颗粒细胞的原代培养并传代，LV-eGFP病毒颗粒体外转染颗粒细胞，观察绿色荧光蛋白（eGFP）的表达情况。大鼠卵巢显微注射的方法以不同转染剂量在体转染大鼠卵巢组织。于转染第3天观察各剂量组卵巢组织切片的eGFP表达情况。确定最佳转染剂量后，分别以转染5天、15天、30天、45天、60天、75天为观察时间点，观察eGFP持续表达及变化情况；并同时检测大鼠全身其他组织器官是否有eGFP的表达。结果：体外转染实验中，在转染第3天可以观察到颗粒细胞内有eGFP的表达，并随着转染时间延长其表达量增多。体内转染大鼠卵巢第5天，不同剂量组大鼠卵巢均有明显eGFP表达；剂量1组（2×106TU病毒颗粒）与剂量2组（10×106TU病毒颗粒）卵巢组织切片荧光半定量分别为0.2311±0.0203及0.2307±0.0199；两组间差异无统计学意义(P=0.976)。随转染时间的延长，绿色荧光蛋白的表达量增加，于转染30天时表达量达到峰值并可以持续高效表达至75天（不同观察时间点卵巢组织荧光强度值分别为0.2307±0.0199，0.3119±0.0213，0.3462±0.0264，0.3568±0.0127，0.3496±0.0133及0.3513±0.0172）。同时，在大鼠全身其它组织器官均有绿色荧光蛋白的高效持续表达。结论：LV-eGFP可以在体外有效转染颗粒细胞，并且可以在活体大鼠卵巢及其他组织器官高效持续地表达。
第二部分：lenti-eGFP-inhba过表达载体的构建及鉴定
目的：构建inhba基因过表达的慢病毒载体（lenti-eGFP-inhba）并观察转染大鼠卵巢颗粒细胞的有效性。方法：pLVX-EGFP-3FLAG质粒系统经EcoR I酶切使之线性化。inhba基因（NM_008380）PCR扩增后同源重组入线性化的表达质粒系统。经转化、菌落阳性克隆鉴定，western blotting检测表达质粒内目的基因的表达情况。构建成功的慢病毒载体（lenti-eGFP-inhba）转染大鼠卵巢颗粒细胞（MOI=20），观察目的基因表达。结果：PCR扩增产物与目的基因大小吻合，重组质粒系统经转化后获得阳性克隆，转染293T细胞可见eGFP-inhba融合蛋白的表达。western blotting获得76kDa分子量大小阳性条带，与融合蛋白分子量大小一致。lenti-eGFP-inhba体外转染大鼠卵巢颗粒细胞，倒置荧光显微镜下可见eGFP的表达。结论：lenti-eGFP-inhba表达载体成功构建，并可以有效转染大鼠颗粒细胞。
第三部分：activinA对大鼠卵泡发育的影响研究
目的：观察慢病毒载体介导inhba基因体内转染大鼠卵巢组织，大鼠生殖内分泌功能的变化。方法：30只SD大鼠随机分为三组：对照组（CON）、inhba基因过表达组（INH）及空病毒载体组（GFP）。Inhba过表达慢病毒载体(LV-eGFP-inhba)通过显微注射转染大鼠卵巢组织，CON组给予相同体积的PBS溶液，GFP组给予相同剂量的空病毒载体（LV-eGFP）。结果：inhba在基因及蛋白水平均成功过表达于INH组大鼠卵巢。窦状卵泡数量在三组间无显著差异（P>0.05）；INH组大鼠窦状卵泡直径大于CON组及GFP组（P<0.05）。ELISA法及放射免疫法检测activin A、雌二醇（E2）、孕激素（P）、卵泡刺激素（FSH）的血清水平在INH组大鼠高于CON组及GFP组大鼠（P<0.05）；INH组黄体生成素（LH）的血清水平低于CON组及GFP组（P>0.05）。雌激素受体（ER-α、ER-β）及FSH受体（FSHR）在mRNA和蛋白的表达水平，INH组大鼠均高于另外两个对照组（P<0.05）；孕激素受体（PR）在三组大鼠的基因及蛋白表达水平无显著差异（P>0.05）；黄体生成素受体（LHR）基因、蛋白表达水平，在INH组低于其他两组（P<0.05）。结论：inhba基因在大鼠卵巢过表达，影响生殖内分泌功能并促进窦状卵泡的发育。
第四部分：activinA促进卵泡发育的分子机制研究
目的：探讨activin A促进颗粒细胞增殖与调控卵泡发育的分子机制。方法：携带inhba基因的慢病毒过表达载体（lenti-eGFP-inhba）体外体内转染大鼠卵巢颗粒细胞及卵巢组织。绘制生长曲线并计算细胞倍增时间；流式细胞技术检测细胞周期及细胞凋亡；免疫组织化学染色检测SCF及c-Kit蛋白在卵巢组织的表达；western blotting检测信号通路蛋白smad2、MERK5、nur77及SCF的表达水平。结果：inhba基因过表达组（INH组）颗粒细胞在体外增殖速率明显高于另外两个对照组（CON组及GFP组），差异具有统计学意义（P<0.05）；INH组细胞倍增时间短于CON组及GFP组（P<0.05）。免疫组化提示大鼠卵巢SCF主要表达于颗粒细胞及黄体细胞，c-Kit主要表达于黄体细胞及各级卵泡的卵母细胞，二者在INH组的表达量高于CON组及GFP组（P<0.05）。western blotting结果提示smad2、MERK5、nur77及SCF蛋白的表达水平在INH组高于CON组及GFP组，差异具有统计学意义（P<0.05）。结论：activin A通过smad2、MERK5、nur77介导的信号通路促进颗粒细胞增殖，颗粒细胞又分泌SCF促进卵泡发育。
Polycystic ovary syndrome (PCOS) is the most common clinicalgynecological endocrine disorder syndrome, and main causes of infertilityfor reproductive age women. Follicular dysplasia is one of thepathophysiological features of PCOS, but the specific pathogenesis is stillunclear. Several researches proved activins hormone can promote cellproliferation and differentiation, regulate possible follicular development.Combined with PCOS patients serum activin hormone expression leveldecreased, we speculated that activins may play an important role in thePCOS follicular developmental disorders. We designed this experiment toclear activins functions in follicular development and possible molecularmechanism in it.
The first part: Lentivirus vectors mediated enhanced greenfluorescence protein gene (LV-eGFP) transfection on rat ovary
Objective: to investigate the transfected efficiency of lentivirus vectorsmediated enhanced green fluorescent protein (eGFP) gene in vitro transfect to the rats’ granular cells and the optimum dosage and the time-effectrelationship on the ovary tissues in vivo. Methods: primary culture of ratovary granular cells was finished, the passage cells were transfected bylentivirus vectors mediated eGFP gene (LV-eGFP) with MOI=20. LV-eGFPwas injected into the rats’ ovary tissues by microinjection. At3days oftransfection, we examine the eGFP expression both in cell in vitro and ovarytissues in vivo. The green fluorescence density of every dosage group in theovaries was calculated. After the rats’ ovaries were microinjected with theoptimum dosage of LV-eGFP, we observed the expression of eGFP in ovariesand others tissues and organs at days5,15,30,45,60and75aftertransfection. Results: after5days of transfection, the eGFP were seen in thegranular cells. For the animal experiment, the expression of eGFP wasobserved at days5of transfection in different dosage group. The greenfluorescence semi-quantitative values for the two groups (2×106TU and10×106TU virosome) were0.2311±0.0203and0.2307±0.0199respectivelyand there was no significance between the two groups (P=0.976). Theexpression of eGFP increased as the transfection time prolongation and wasat its peak at days30of transfection and can last high-level expression to75days (the green fluorescence density of every time point is0.2307±0.0199，0.3119±0.0213，0.3462±0.0264，0.3568±0.0127，0.3496±0.0133and0.3513±0.0172). Furthermore, there were efficient and durable expressionof eGFP at other tissues and organs in rats. Conclusion: LV-eGFP may transfect successfully on rats’ ovary granular cells in vitro and ovary tissuesand other organs in vivo simultaneously, the expression of eGFP ishighly-efficient and durable.
The second part: The construction and identification oflentivirus vectors mediated inhba gene overexpression
Objective: To construct lentivirus overexpression vectors of inhbagene (lenti-eGFP-inhba) and observe the effectiveness of it transfectedovarian granulosa cells of rats in vitro. Methods: pLVX-EGFP-3FLAGplasmid system linearization was carried out via EcoR I enzyme. Inhba gene(NM_008380) was amplified by PCR and recombinated homologously intothe linearized plasmid system. The plasmid was constructed viatransformation and colony positive clone identification. Western blottingwas used to test expression in protein level that the target gene in plasmid.Lenti-eGFP-inhba transfected rat ovarian granulosa cells (MOI=20) in vitro,the eGFP and inhba gene expression was observed by inverted fluorescencemicroscope. Results: The PCR amplification product was consistant withthe size of target gene. Recombinant plasmid system obtained positiveclones after transformation; the expression of eGFP-inhba fusion proteinwas visible in which transfected293T cells.76kda positive stripe Westernblotting acquired was accordance with the molecular weight of the fusionprotein. Lenti-eGFP-inhba transfection into rat ovarian granulosa cells invitro, the expression of eGFP was observed by inverted fluorescence microscope. Conclusion: lenti-eGFP-inhba overexpression vector was toconstructed successfully, and can effective transfection granulosa cells inrats.
The third part: Changes in reproductive endocrine in ratfollowing intraovary microinjection of inhba lentivirus vectors
Objective: To investigate the reproductive endocrine changes afterinhba overexpression into rat ovary. Methods: Thirty Sprague-Dawley ratswere randomly assigned to three groups. Inhba overexpression lentivirusvectors (LV-eGFP-inhba) were microinjected into rat ovary (INH group);Control animals received the same amount lentivirus vector empty (CONgroup) or LV-eGFP (GFP group). Antral follicle amount and diameter werecounted and serum level of activin A, E2, P, FSH, and LH and the expressionof ER-α, ER-β, PR, FSHR, and LHR were measured. Results: There was nosignificant difference among three groups in antral follicle amount (P>0.05);antral follicle diameter was increased in INH group rats compared with theother group rats (P<0.05). Serum levels of activin A, E2, P, and FSHhormones were increased and LH was decreased in INH group ratscompared with the other group rats (P<0.05). The mRNA and proteinexpression of ER-α, ER-β, FSHR was higher in INH group rats than that inthe other group rats (P<0.05). There was no significant difference in mRNAand protein expression of PR among the three group rats (P>0.05), LHRexpression was decreased in INH group rats compared with the other two group rats (P<0.05). Conclusion: inhba overexpression in rat ovary in vivomay change reproductive endocrine function.
The forth part: Molecular mechanism of activin A regulationfollicle development in rat
Objective: To study the molecular mechanism of activin A hormonepromotes follicular granulosa cell proliferation and regulates follicledevelopment. Methods: Inhba gene overexpression lentivirus vectors(lenti-eGFP-inhba) were transfected into rat ovarian granulosa cells in vitroand ovarian tissue in vivo respectively. We draw the cell growth curve andcalculate the cell doubling time; detect the cell cycle and cell apoptosis byFlow cytometry technology; observe SCF and c-Kit protein expression inovarian tissue through Immunohistochemical staining; estimate expressionlevel of signal pathway proteins smad2, MERK5, nur77and SCF byWestern blotting technology. Results: Granulosa cells proliferation rate ininhba gene overexpression group (INH) was higher than that in the other twocontrol groups (CON group and GFP group) in vitro, the difference wasstatistically significant (P<0.05); cell doubling time in INH group wasshorter than that in both the CON group and GFP group (P<0.05).Immunohistochemical staining suggested SCF protein is mainly expressedin ovarian granulosa cells and corpus luteum cells; c-Kit is mainly expressedin luteal cells and the follicular oocytes of different level follicles. Both ofthe two proteins expression in INH group was higher than that in CON group and GFP group (P <0.05). Western blotting results indicated Smad2,MERK5, nur77and SCF protein expression level in INH group was higherthan that in CON group and GFP group, the statistical difference issignificance (P <0.05). Conclusions: activin A could promote granulosacell proliferation through smad2, MERK5, nur77mediated signalingpathway and secrete SCF protein to promote follicle development.
第一部分：慢病毒载体（LV-eGFP）转染大鼠卵巢颗粒细胞的体内外实验研究
目的：探讨LV-eGFP体外转染卵巢颗粒细胞的有效性及体内转染大鼠卵巢组织的最佳剂量及时效性。方法：大鼠卵巢颗粒细胞的原代培养并传代，LV-eGFP病毒颗粒体外转染颗粒细胞，观察绿色荧光蛋白（eGFP）的表达情况。大鼠卵巢显微注射的方法以不同转染剂量在体转染大鼠卵巢组织。于转染第3天观察各剂量组卵巢组织切片的eGFP表达情况。确定最佳转染剂量后，分别以转染5天、15天、30天、45天、60天、75天为观察时间点，观察eGFP持续表达及变化情况；并同时检测大鼠全身其他组织器官是否有eGFP的表达。结果：体外转染实验中，在转染第3天可以观察到颗粒细胞内有eGFP的表达，并随着转染时间延长其表达量增多。体内转染大鼠卵巢第5天，不同剂量组大鼠卵巢均有明显eGFP表达；剂量1组（2×106TU病毒颗粒）与剂量2组（10×106TU病毒颗粒）卵巢组织切片荧光半定量分别为0.2311±0.0203及0.2307±0.0199；两组间差异无统计学意义(P=0.976)。随转染时间的延长，绿色荧光蛋白的表达量增加，于转染30天时表达量达到峰值并可以持续高效表达至75天（不同观察时间点卵巢组织荧光强度值分别为0.2307±0.0199，0.3119±0.0213，0.3462±0.0264，0.3568±0.0127，0.3496±0.0133及0.3513±0.0172）。同时，在大鼠全身其它组织器官均有绿色荧光蛋白的高效持续表达。结论：LV-eGFP可以在体外有效转染颗粒细胞，并且可以在活体大鼠卵巢及其他组织器官高效持续地表达。
第二部分：lenti-eGFP-inhba过表达载体的构建及鉴定
目的：构建inhba基因过表达的慢病毒载体（lenti-eGFP-inhba）并观察转染大鼠卵巢颗粒细胞的有效性。方法：pLVX-EGFP-3FLAG质粒系统经EcoR I酶切使之线性化。inhba基因（NM_008380）PCR扩增后同源重组入线性化的表达质粒系统。经转化、菌落阳性克隆鉴定，western blotting检测表达质粒内目的基因的表达情况。构建成功的慢病毒载体（lenti-eGFP-inhba）转染大鼠卵巢颗粒细胞（MOI=20），观察目的基因表达。结果：PCR扩增产物与目的基因大小吻合，重组质粒系统经转化后获得阳性克隆，转染293T细胞可见eGFP-inhba融合蛋白的表达。western blotting获得76kDa分子量大小阳性条带，与融合蛋白分子量大小一致。lenti-eGFP-inhba体外转染大鼠卵巢颗粒细胞，倒置荧光显微镜下可见eGFP的表达。结论：lenti-eGFP-inhba表达载体成功构建，并可以有效转染大鼠颗粒细胞。
第三部分：activinA对大鼠卵泡发育的影响研究
目的：观察慢病毒载体介导inhba基因体内转染大鼠卵巢组织，大鼠生殖内分泌功能的变化。方法：30只SD大鼠随机分为三组：对照组（CON）、inhba基因过表达组（INH）及空病毒载体组（GFP）。Inhba过表达慢病毒载体(LV-eGFP-inhba)通过显微注射转染大鼠卵巢组织，CON组给予相同体积的PBS溶液，GFP组给予相同剂量的空病毒载体（LV-eGFP）。结果：inhba在基因及蛋白水平均成功过表达于INH组大鼠卵巢。窦状卵泡数量在三组间无显著差异（P>0.05）；INH组大鼠窦状卵泡直径大于CON组及GFP组（P<0.05）。ELISA法及放射免疫法检测activin A、雌二醇（E2）、孕激素（P）、卵泡刺激素（FSH）的血清水平在INH组大鼠高于CON组及GFP组大鼠（P<0.05）；INH组黄体生成素（LH）的血清水平低于CON组及GFP组（P>0.05）。雌激素受体（ER-α、ER-β）及FSH受体（FSHR）在mRNA和蛋白的表达水平，INH组大鼠均高于另外两个对照组（P<0.05）；孕激素受体（PR）在三组大鼠的基因及蛋白表达水平无显著差异（P>0.05）；黄体生成素受体（LHR）基因、蛋白表达水平，在INH组低于其他两组（P<0.05）。结论：inhba基因在大鼠卵巢过表达，影响生殖内分泌功能并促进窦状卵泡的发育。
第四部分：activinA促进卵泡发育的分子机制研究
目的：探讨activin A促进颗粒细胞增殖与调控卵泡发育的分子机制。方法：携带inhba基因的慢病毒过表达载体（lenti-eGFP-inhba）体外体内转染大鼠卵巢颗粒细胞及卵巢组织。绘制生长曲线并计算细胞倍增时间；流式细胞技术检测细胞周期及细胞凋亡；免疫组织化学染色检测SCF及c-Kit蛋白在卵巢组织的表达；western blotting检测信号通路蛋白smad2、MERK5、nur77及SCF的表达水平。结果：inhba基因过表达组（INH组）颗粒细胞在体外增殖速率明显高于另外两个对照组（CON组及GFP组），差异具有统计学意义（P<0.05）；INH组细胞倍增时间短于CON组及GFP组（P<0.05）。免疫组化提示大鼠卵巢SCF主要表达于颗粒细胞及黄体细胞，c-Kit主要表达于黄体细胞及各级卵泡的卵母细胞，二者在INH组的表达量高于CON组及GFP组（P<0.05）。western blotting结果提示smad2、MERK5、nur77及SCF蛋白的表达水平在INH组高于CON组及GFP组，差异具有统计学意义（P<0.05）。结论：activin A通过smad2、MERK5、nur77介导的信号通路促进颗粒细胞增殖，颗粒细胞又分泌SCF促进卵泡发育。
Polycystic ovary syndrome (PCOS) is the most common clinicalgynecological endocrine disorder syndrome, and main causes of infertilityfor reproductive age women. Follicular dysplasia is one of thepathophysiological features of PCOS, but the specific pathogenesis is stillunclear. Several researches proved activins hormone can promote cellproliferation and differentiation, regulate possible follicular development.Combined with PCOS patients serum activin hormone expression leveldecreased, we speculated that activins may play an important role in thePCOS follicular developmental disorders. We designed this experiment toclear activins functions in follicular development and possible molecularmechanism in it.
The first part: Lentivirus vectors mediated enhanced greenfluorescence protein gene (LV-eGFP) transfection on rat ovary
Objective: to investigate the transfected efficiency of lentivirus vectorsmediated enhanced green fluorescent protein (eGFP) gene in vitro transfect to the rats’ granular cells and the optimum dosage and the time-effectrelationship on the ovary tissues in vivo. Methods: primary culture of ratovary granular cells was finished, the passage cells were transfected bylentivirus vectors mediated eGFP gene (LV-eGFP) with MOI=20. LV-eGFPwas injected into the rats’ ovary tissues by microinjection. At3days oftransfection, we examine the eGFP expression both in cell in vitro and ovarytissues in vivo. The green fluorescence density of every dosage group in theovaries was calculated. After the rats’ ovaries were microinjected with theoptimum dosage of LV-eGFP, we observed the expression of eGFP in ovariesand others tissues and organs at days5,15,30,45,60and75aftertransfection. Results: after5days of transfection, the eGFP were seen in thegranular cells. For the animal experiment, the expression of eGFP wasobserved at days5of transfection in different dosage group. The greenfluorescence semi-quantitative values for the two groups (2×106TU and10×106TU virosome) were0.2311±0.0203and0.2307±0.0199respectivelyand there was no significance between the two groups (P=0.976). Theexpression of eGFP increased as the transfection time prolongation and wasat its peak at days30of transfection and can last high-level expression to75days (the green fluorescence density of every time point is0.2307±0.0199，0.3119±0.0213，0.3462±0.0264，0.3568±0.0127，0.3496±0.0133and0.3513±0.0172). Furthermore, there were efficient and durable expressionof eGFP at other tissues and organs in rats. Conclusion: LV-eGFP may transfect successfully on rats’ ovary granular cells in vitro and ovary tissuesand other organs in vivo simultaneously, the expression of eGFP ishighly-efficient and durable.
The second part: The construction and identification oflentivirus vectors mediated inhba gene overexpression
Objective: To construct lentivirus overexpression vectors of inhbagene (lenti-eGFP-inhba) and observe the effectiveness of it transfectedovarian granulosa cells of rats in vitro. Methods: pLVX-EGFP-3FLAGplasmid system linearization was carried out via EcoR I enzyme. Inhba gene(NM_008380) was amplified by PCR and recombinated homologously intothe linearized plasmid system. The plasmid was constructed viatransformation and colony positive clone identification. Western blottingwas used to test expression in protein level that the target gene in plasmid.Lenti-eGFP-inhba transfected rat ovarian granulosa cells (MOI=20) in vitro,the eGFP and inhba gene expression was observed by inverted fluorescencemicroscope. Results: The PCR amplification product was consistant withthe size of target gene. Recombinant plasmid system obtained positiveclones after transformation; the expression of eGFP-inhba fusion proteinwas visible in which transfected293T cells.76kda positive stripe Westernblotting acquired was accordance with the molecular weight of the fusionprotein. Lenti-eGFP-inhba transfection into rat ovarian granulosa cells invitro, the expression of eGFP was observed by inverted fluorescence microscope. Conclusion: lenti-eGFP-inhba overexpression vector was toconstructed successfully, and can effective transfection granulosa cells inrats.
The third part: Changes in reproductive endocrine in ratfollowing intraovary microinjection of inhba lentivirus vectors
Objective: To investigate the reproductive endocrine changes afterinhba overexpression into rat ovary. Methods: Thirty Sprague-Dawley ratswere randomly assigned to three groups. Inhba overexpression lentivirusvectors (LV-eGFP-inhba) were microinjected into rat ovary (INH group);Control animals received the same amount lentivirus vector empty (CONgroup) or LV-eGFP (GFP group). Antral follicle amount and diameter werecounted and serum level of activin A, E2, P, FSH, and LH and the expressionof ER-α, ER-β, PR, FSHR, and LHR were measured. Results: There was nosignificant difference among three groups in antral follicle amount (P>0.05);antral follicle diameter was increased in INH group rats compared with theother group rats (P<0.05). Serum levels of activin A, E2, P, and FSHhormones were increased and LH was decreased in INH group ratscompared with the other group rats (P<0.05). The mRNA and proteinexpression of ER-α, ER-β, FSHR was higher in INH group rats than that inthe other group rats (P<0.05). There was no significant difference in mRNAand protein expression of PR among the three group rats (P>0.05), LHRexpression was decreased in INH group rats compared with the other two group rats (P<0.05). Conclusion: inhba overexpression in rat ovary in vivomay change reproductive endocrine function.
The forth part: Molecular mechanism of activin A regulationfollicle development in rat
Objective: To study the molecular mechanism of activin A hormonepromotes follicular granulosa cell proliferation and regulates follicledevelopment. Methods: Inhba gene overexpression lentivirus vectors(lenti-eGFP-inhba) were transfected into rat ovarian granulosa cells in vitroand ovarian tissue in vivo respectively. We draw the cell growth curve andcalculate the cell doubling time; detect the cell cycle and cell apoptosis byFlow cytometry technology; observe SCF and c-Kit protein expression inovarian tissue through Immunohistochemical staining; estimate expressionlevel of signal pathway proteins smad2, MERK5, nur77and SCF byWestern blotting technology. Results: Granulosa cells proliferation rate ininhba gene overexpression group (INH) was higher than that in the other twocontrol groups (CON group and GFP group) in vitro, the difference wasstatistically significant (P<0.05); cell doubling time in INH group wasshorter than that in both the CON group and GFP group (P<0.05).Immunohistochemical staining suggested SCF protein is mainly expressedin ovarian granulosa cells and corpus luteum cells; c-Kit is mainly expressedin luteal cells and the follicular oocytes of different level follicles. Both ofthe two proteins expression in INH group was higher than that in CON group and GFP group (P <0.05). Western blotting results indicated Smad2,MERK5, nur77and SCF protein expression level in INH group was higherthan that in CON group and GFP group, the statistical difference issignificance (P <0.05). Conclusions: activin A could promote granulosacell proliferation through smad2, MERK5, nur77mediated signalingpathway and secrete SCF protein to promote follicle development.
引文
[1] Bart C. J. M. Fauser, Basil C. Tarlatzis, Robert W. Rebar, et al. Consensus onwomen’ s health aspects of polycystic ovary syndrome (PCOS): the AmsterdamESHRE/ASRM-Sponsored3rd PCOS Consensus Workshop Group [J]. Fertilityand Sterility,2012,97(1), doi:10.1016/j.fert nstert.2011.09.024.
[2] Robert A. Wild, Manfredi Rizzo, Sheri Clifton, et al. Lipid levels in polycysticovary syndrome: systematic review and meta-analysis [J]. Fertility and Sterility,2011,95(3):1073-1079.
[3] Lisa J. Moran, Boyd J. Strauss, Helena J. Teede. Diabetes risk score in thediagnostic categories of polycystic ovary syndrome [J]. Fertility and Sterility,2011, doi:10.1016/j.fertnstert.2011.01.133.
[4] Gautam N. Allahbadia, Rubina Merchant. Polycystic ovary syndrome and impacton health [J]. Middle East Fertility Society Journal,2011,16:19–37.
[5] The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.Revised2003consensus on diagnostic criteria and long-term health risks relatedto polycystic ovary syndrome (PCOS)[J]. Human Reproduction,2004,19(1):41-47.
[6] March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: Theprevalence of polycystic ovary syndrome in a community sample assessed undercontrasting diagnostic criteria [J]. Hum Reprod,2010,25:544-551.
[7] Mahesh, V. B. Hirsutism, virilism, polycystic ovarian disease, and thesteroid-gonadotropin-feedback system: a career retrospective [J]. Am J PhysiolEndocrinol Metab,2012,302(1): E4-E18.
[8]王增杰，王秀霞.辽宁省汉族育龄妇女多囊卵巢综合征患病情况的流行病学调查[M].中国医科大学硕士学位论文，2009:1-5.
[9]赵君利,陈子江.多囊卵巢综合征的流行病学调查及相关基础研究[M].山东大学博士学位论文，2006:1-3.
[10]陈红,宋学茹.天津地区育龄期妇女多囊卵巢综合征临床特征及发病相关因素的流行病学调查研究[M].天津医科大学硕士学位论文，2009:1-3.
[11]Sathyapalan, T., Atkin, S. L. Recent advances in cardiovascular aspects ofpolycystic ovary syndrome [J]. Eur J Endocrinol,2012,166(4):575-583.
[12]Tamara Baer, Amy DiVasta. A longitudinal comparison of cardiovascular riskfactors in overweight and normal-weight adolescents with polycyctic ovarysyndrome (PCOS)[J]. Poster Abstracts,2011,48: S19.
[13]De Groot PC, Dekkers OM, Romijn JA, et al. Hum. Reprod [J]. Update,2011, doi:10.1093/humupd/dmr001.
[14]Mahesh, V. B. Hirsutism, virilism, polycystic ovarian disease, and thesteroid-gonadotropin-feedback system: a career retrospective [J]. Am J PhysiolEndocrinol Metab,2012,302(1): E4-E18.
[15]Bulent O. Yildiz, Ricardo Azziz. Ovarian and adipose tissue dysfunction inpolycystic ovary syndrome: report of the4th special scientific meeting of theAndrogen Excess and PCOS Society [J]. Fertility and Sterility,2010,94(2):690-693.
[16]Berstein, L. M. Metformin in obesity, cancer and aging: addressing controversies[J]. Aging (Albany NY),2012,4(5):320-329.
[17]Konstantinos G. Michalakis, James H. Segars. The role of adiponectin inreproduction: from polycystic ovary syndrome to assisted reproduction [J].Fertility and Sterility,2010,94(6):1949-1957.
[18]Andrea Repaci, Alessandra Gambineri, Renato Pasquali. The role of low-gradeinflammation in the polycystic ovary syndrome [J]. Mol. Cell. Endocrinol,2010,doi:10.1016/j.mce.2010.08.002.
[19]Matthew C. Ernst, Christopher J. Sinal. Chemerin: at the crossroads ofinflammation and obesity [J]. Trends in Endocrinology and Metabolism,2010,21(11):660-667.
[20]Bowen Jiang, Heather A. Kenna, Natalie L. Rasgon. Genetic overlap betweenpolycystic ovary syndrome and bipolar disorder: The endophenotype hypothesis[J]. Medical Hypotheses,2009,73:996–1004.
[21]郭海燕,赵晓明,高敏芝.多囊卵巢综合征与相关基因多态性的研究进展[J].生殖与避孕,2009,29(5):319-323.
[22]Anastasios Ioannidis, Eleni Ikonomi, Niki L. Dimou. Polymorphisms of theinsulin receptor and the insulin receptor substrates genes in polycystic ovarysyndrome: A Mendelian randomization meta-analysis [J]. Molecular Genetics andMetabolism,2010,99:174–183.
[23]Catherine G. Baptiste, Marie-Claude Battista, Andréanne Trottier, te al. Insulinand hyperandrogenism in women with polycystic ovary syndrome [J]. Journal ofSteroid Biochemistry&Molecular Biology,2010,122:42–52.
[24]Thozhukat Sathyapalan, Stephen L. Atkin. Mediators of Inflammation inPolycystic Ovary Syndrome in Relation to Adiposity [J]. Mediators ofInflammation,2010:1-5. doi:10.1155/2010/758656.
[25]Burt Solorzano, C. M. Beller, J. P. Abshire, M. Y., et al. Neuroendocrinedysfunction in polycystic ovary syndrome [J]. Steroids,2012,77(4):332-337.
[26]Walton, K. L., Makanji, Y., Harrison, C. A. New insights into the mechanisms ofactivin action and inhibition [J]. Mol Cell Endocrinol,2012,359(1-2):2-12.
[27]Lotinun, S., Pearsall, R. S., Horne, W. C., Baron, R. Activin receptor signaling: apotential therapeutic target for osteoporosis [J]. Curr Mol Pharmacol,2012,5(2):195-204.
[28]Shelling, A. N. Mutations in inhibin and activin genes associated with humandisease [J]. Mol Cell Endocrinol,2012,359(1-2):113-120.
[29]Norman, R. J., Milner, C. R., Groome, N. P., and Robertson, D. M. Circulatingfollistatin concentrations are higher and activin concentrations are lower inpolycystic ovarian syndrome [J]. Hum Reprod2001;16(4):668-672.
[30]de Kretser, D. M., O'Hehir, R. E., Hardy, C. L., Hedger, M. P. The roles of activinA and its binding protein, follistatin, in inflammation and tissue repair [J]. MolCell Endocrinol,2012,359(1-2):101-106.
[31]Payne, C., King, J., Hay, D. The role of activin/nodal and Wnt signaling inendoderm formation [J]. Vitam Horm,2011,85:207-216.
[1] David Escors, Karine Breckpot. Lentiviral vectors in gene therapy: their currentstatus and future potential [J]. Arch Immunol Ther Exp (Warsz),2010,58(2):107–119. doi:10.1007/s00005-010-0063-4.
[2] David V. Schaffer, James T. Koerber, and Kwang-il Lim. Molecular Engineeringof Viral Gene Delivery Vehicles [J]. Annu Rev Biomed Eng,2008,10:169–194.doi:10.1146/annurev.bioeng.10.061807.160514.
[3] Eun Young Kim, Young Bin Hong and Zhennan Lai, et al. Expression andsecretion of human glucocerebrosidase mediated by recombinant lentivirusvectors in vitro and in vivo: implications for gene therapy of Gaucher disease [J].Biochemical and Biophysical Research Communications,2004,318:381–390.
[4] Qin Hua, Chunhua Chena and Nikan H. Khatibi, et al. Lentivirus-mediatedtransfer of MMP-9shRNA provides neuroprotection following focal ischemicbrain injury in rats [J]. BRAIN RESEARCH,2011,1367:347–359.
[5] Sakuma, T., Barry, M. A., Ikeda, Y. Lentiviral vectors: basic to translational [J].Biochem J,2012,443(3):603-618.
[6] Rossetti, M., Cavarelli, M., Gregori, S., Scarlatti, G. HIV-derived vectors for genetherapy targeting dendritic cells [J]. Adv Exp Med Biol,2013,762:239-261.
[7] Picanco-Castro, V., de Sousa Russo-Carbolante, E. M., Tadeu Covas, D. Advancesin lentiviral vectors: a patent review [J]. Recent Pat DNA Gene Seq,2012,6(2):82-90.
[8] Mantovani J, Charrier S, Eckenberg R, Saurin W, Danos O, Perea J, Galy A.Diverse genomic integration of a lentiviral vector developed for the treatment ofWiskott-Aldrich syndrome [J]. J Gene Med,2009,11(8):645-654.
[9] Peter C. Huszthy, Tsanan Giroglou and Oleg Tsinkalovsky, et al. Remission ofInvasive, Cancer Stem-Like Glioblastoma Xenografts Using LentiviralVector-Mediated Suicide Gene Therapy [J]. PLoS One,2009,4(7): e6314.
[10]Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy andsafety of gene therapy for Wiskott-Aldrich syndrome in preclinical models [J].Molecular Therapy,2009,17:1073–1082.[PubMed:19259069]
[11]Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy:targeting activation pathways through genetic modification [J]. EMID-DT,2009,9(4):328-43.
[12]VB O’Leary, SV Ovsepian and A Raghunath, et al. Innocuous full-lengthbotulinum neurotoxin targets and promotes the expression of lentiviral vectors incentral and autonomic neurons [J]. Gene Therapy,2011,18:656–665.
[13] Roth, S. D., Schuttrumpf, J., Milanov, P., Abriss, D., Ungerer, C., Quade-Lyssy,P., Simpson, J. C., Pepperkok, R., Seifried, E., Tonn, T. Chemical chaperonesimprove protein secretion and rescue mutant factor VIII in mice with hemophiliaA [J]. PLoS One,2012,7(9): e44505.
[14]李红,曾卫森,罗琛,等. Bax/Bak在抑制人颗粒细胞凋亡中的作用[J].南方医科大学学报,2009,29(12):2367-2370.
[15]Gautam N. Allahbadia and Rubina Merchant. Polycystic ovary syndrome andimpact on health [J]. Middle East Fertil Soc J,2010, doi:10.1016/j.mefs.2010.10.002.
[1] Sven Ansorge, Olivier Henry, Amine Kamen. Recent progress in lentiviral vectormass production [J]. Biochemical Engineering Journal,2010,48:362–377.
[2] Smed-Sorensen, A., Lore, K. Targeting dendritic cells for improved HIV-1vaccines [J]. Adv Exp Med Biol,2013,762:263-288.
[3] Primo, M. N., Bak, R. O., Mikkelsen, J. G. Lentiviral vectors for cutaneous RNAmanaging [J]. Exp Dermatol,2012,21(3):162-170.
[4] Warnock, J. N., Daigre, C., Al-Rubeai, M. Introduction to viral vectors [J].Methods Mol Biol,2011,737:1-25.
[5] Di Nunzio, F., Felix, T., Arhel, N. J., Nisole, S., Charneau, P., Beignon, A. S.HIV-derived vectors for therapy and vaccination against HIV [J]. Vaccine,2012,30(15):2499-2509.
[6] Ruiz, M., Deglon, N. Viral-mediated overexpression of mutant huntingtin tomodel HD in various species [J]. Neurobiol Dis,2012,48(2):202-211.
[7] Durand, S., Cimarelli, A. The inside out of lentiviral vectors [J]. Viruses,2011,3(2):132-159.
[8] Rao, M. S., Malik, N. Assessing iPSC reprogramming methods for their suitabilityin translational medicine [J]. J Cell Biochem,2012,113(10):3061-3068.
[9] Mochiduki, Y., Okita, K. Methods for iPS cell generation for basic research andclinical applications [J]. Biotechnol J,2012,7(6):789-797.
[10] Hirai, H. Basic research on cerebellar gene therapy using lentiviral vectors [J].Cerebellum,2012,11(2):443-445.
[1] Kosova, G., Urbanek, M. Genetics of the polycystic ovary syndrome [J].Molecular and Cellular Endocrinology (2012), http://dx.doi.org/10.1016/j.mce.2012.10.009
[2] Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., Azziz, R. Polycystic ovarysyndrome: etiology, pathogenesis and diagnosis [J]. Nat Rev Endocrinol,2011,7(4):219-231.
[3] Christine M. Burt Solorzano, Jennifer P. Beller, Michelle Y. Abshire, Jessicah S.Collins, Christopher R. McCartney, John C. Marshall. Neuroendocrinedysfunction in polycystic ovary syndrome [J]. Steroids,2012,77:332–337.
[4] Cruz, G., Barra, R., Gonzalez, D., Sotomayor-Zarate, R., Lara, H. E. Temporalwindow in which exposure to estradiol permanently modifies ovarian functioncausing polycystic ovary morphology in rats [J]. Fertil Steril,2012,98(5):1283-1290.
[5] Shi, D., Vine, D. F. Animal models of polycystic ovary syndrome: a focusedreview of rodent models in relationship to clinical phenotypes andcardiometabolic risk [J]. Fertil Steril,2012,98(1):185-193.
[6] Walters, K. A., Allan, C. M., Handelsman, D. J. Rodent models for humanpolycystic ovary syndrome [J]. Biol Reprod,2012,86(5):149,141-112.
[7] Miyazono, K., Kamiya, Y., Morikawa, M.. Bone morphogenetic protein receptorsand signal transduction [J]. J. Biochem,2010,147:35–51.
[8] Phil G. Knight, Leanne Satchell, Claire Glister. Intra-ovarian roles of activins andinhibins [J]. Molecular and Cellular Endocrinology,2012,359:53–65.
[9] Xia, Y., Schneyer, A. L. The biology of activin: recent advances in structure,regulation and function [J]. J Endocrinol,2009,202(1):1-12.
[10]McLaughlin, M., Bromfield, J. J., Albertini, D. F., Telfer, E. E. Activin promotesfollicular integrity and oogenesis in cultured pre-antral bovine follicles [J]. MolHum Reprod,2010,16(9):644-653.
[11]Thomas, F. H., Armstrong, D. G., Telfer, E. E. Activin promotes oocytedevelopment in ovine preantral follicles in vitro [J]. Reprod Biol Endocrinol,2003,1:76.
[12]Zhao, J., Taverne, M. A., van der Weijden, G. C., Bevers, M. M., van den Hurk, R.Effect of activin A on in vitro development of rat preantral follicles andlocalization of activin A and activin receptor II [J]. Biol Reprod,2001,65(3):967-977.
[13]Kipp, J. L., Kilen, S. M., Woodruff, T. K., Mayo, K. E. Activin regulates estrogenreceptor gene expression in the mouse ovary [J]. J Biol Chem,2007,282(50):36755-36765.
[14]Xia, Y., Schneyer, A. L. The biology of activin: recent advances in structure,regulation and function [J]. J Endocrinol,2009,202(1):1-12.
[15]Christopher A. Pearl, Holly Mason, Janet F. Roser. Immunolocalization ofestrogen receptor alpha, estrogen receptor beta and androgen receptor in the pre-,peri-and post-pubertal stallion testis [J]. Animal Reproduction Science,2011,125:103–111.
[16]Douglas A. Gibson, Philippa T.K. Saunders. Estrogen dependent signaling inreproductive tissues–A role for estrogen receptors and estrogen related receptors[J]. Molecular and Cellular Endocrinology,2012,348:361–372.
[17]Renoir, J. M., Marsaud, V., Lazennec, G. Estrogen receptor signaling as a targetfor novel breast cancer therapeutics [J]. Biochem Pharmacol,2013,85(4):449-465.
[1] Wongbandue, G., Jewgenow, K., Chatdarong, K. Effects of thyroxin (T(4)) andactivin A on in vitro growth of preantral follicles in domestic cats [J].Theriogenology,2012,79(5):824-832.
[2] Hofland, J., van Weerden, W. M., Steenbergen, J., Dits, N. F., Jenster, G., de Jong,F. H. Activin A stimulates AKR1C3expression and growth in human prostatecancer [J]. Endocrinology,2012,153(12):5726-5734.
[3] Roberts-Galbraith, R. H., Newmark, P. A. Follistatin antagonizes Activin signalingand acts with Notum to direct planarian head regeneration [J]. Proc Natl Acad SciUSA,2013,110(4):1363-1368.
[4] Mathew, S., Jaramillo, M.,Zhang, X., Zhang, L. A., Soto-Gutierrez, A., Banerjee, I.Analysis of alternative signaling pathways of endoderm induction of humanembryonic stem cells identifies context specific differences [J]. BMC Syst Biol,2012,6:154.
[5] Dong Huansheng, Pan Qingjie, Zhang Hanqiong, Zhang Lianjun, Chen Bo, YueWenbin. Estrogen inhibits the early development of mouse follicles throughregulating the expression of Kit ligand [J]. Biochemical and BiophysicalResearch Communications,2011,410:659–664.
[6] Lennartsson, J., and Ronnstrand, L. Stem cell factor receptor/c-Kit: from basicscience to clinical implications [J]. Physiol Rev,2012,92(4):1619-1649.
[7] Daniel A. Dumesic, JoAnne S. Richards. Ontogeny of the ovary in polycysticovary syndrome [J]. Fertility and Sterility,2013, http://dx.d oi.org/10.1016/j.fertnstert.2013.02.011.
[8] Zapater, C., Chauvigne, F., Tingaud-Sequeira, A., Finn, R. N., Cerda, J. Geneticmanipulation of keratinocyte stem cells with lentiviral vectors [J]. Methods MolBiol,2013,989:143-151.
[9] Hennet, M. L., Combelles, C. M. The antral follicle: a microenvironment foroocyte differentiation [J]. Int J Dev Biol,2012,56(10-11-12):819-831.
[10]Rosenbusch, B. The potential significance of binovular follicles and binucleategiant oocytes for the development of genetic abnormalities [J]. J Genet,2012,91(3):397-404.
[11]Beresford, D. V., Sutcliffe, J. F. Field measurements of stable fly (Diptera:Muscidae) demography, fecundity, and survival based on daily trap catches at abeef farm in southern Ontario over a5-yr period [J]. J Med Entomol,2012,49(6):1262-1269.
[12]Barros, C. M., Satrapa, R. A., Castilho, A. C., Fontes, P. K., Razza, E. M., Ereno,R. L., Nogueira, M. F. Effect of superstimulatory treatments on the expression ofgenes related to ovulatory capacity, oocyte competence and embryo developmentin cattle [J]. Reprod Fertil Dev,2012,25(1):17-25.
[13] Pan, T. L., Wang, P. W. Explore the Molecular Mechanism of Apoptosis Inducedby Tanshinone IIA on Activated Rat Hepatic Stellate Cells [J]. Evid BasedComplement Alternat Med,2012:734987.
[14] Maekawa, T. Cell-cycle regulators as molecular target [J]. Nihon Rinsho,2012,70Suppl8:119-124.
[15]I.M.T. Lima, I.R. Brito, G.Q. Rodrigues, et al. Presence of c-kit mRNA in goatovaries and improvement ofin vitro preantral follicle survival and developmentwith kit ligand [J]. Molecular and Cellular Endocrinology,2011,345:38–47.
[16]Janson, C., Kasahara, N., Prendergast, G. C., Colicelli, J. RIN3is a negativeregulator of mast cell responses to SCF [J]. PLoS One,2012,7(11): e49615.
[17]Ouni, I., Flick, K., Kaiser, P. A transcriptional activator is part of an SCF ubiquitinligase to control degradation of its cofactors [J]. Mol Cell,2010,40(6):954-964.
[18]Guglielmo, M. C., Ricci, G., Catizone, A., et al. The effect of hepatocyte growthfactor on the initial stages of mouse follicle development [J]. J Cell Physiol,2011,226(2):520-529.
[1] Stepto, N. K., Cassar, S., Joham, A. E., et al. Women with polycystic ovarysyndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemicclamp [J]. Hum Reprod,2013,28(3):777-784.
[2] Ravn, P., Haugen, A. G., Glintborg, D. Overweight in polycystic ovary syndrome.An update on evidence based advice on diet, exercise and metformin use forweight loss [J]. Minerva Endocrinol,2013,38(1):59-76.
[3] Sir-Petermann, T., Ladron de Guevara, A., Villarroel, A. C., et al. Polycystic ovarysyndrome and pregnancy [J]. Rev Med Chil,2012,140(7):919-925.
[4] Saxena, P., Prakash, A., Nigam, A., et al. Polycystic ovary syndrome: Is obesity asine qua non? A clinical, hormonal, and metabolic assessment in relation to bodymass index [J]. Indian J Endocrinol Metab,2012,16(6):996-999.
[5] Kosova, G., Urbanek, M. Genetics of the polycystic ovary syndrome [J]. Mol CellEndocrinol,2012. doi:10.1016/j.mce.2012.10.009.[Epub ahead of print]
[6] Pangaribuan, B., Yusuf, I., Mansyur, M., Wijaya, A. Serum adiponectin andresistin in relation to insulin resistance and markers of hyperandrogenism in leanand obese women with polycystic ovary syndrome [J]. Ther Adv EndocrinolMetab,2011,2(6):235-245.
[7] Barber, T. M., Franks, S. Adipocyte biology in polycystic ovary syndrome [J]. MolCell Endocrinol,2012, doi:10.1016/j.mce.2012.10.010.[Epub ahead of print]
[8] Diamanti-Kandarakis, E., Dunaif, A. Insulin resistance and the polycystic ovarysyndrome revisited: an update on mechanisms and implications [J]. Endocr Rev,2012,33(6):981-1030.
[9] Vosnakis, C., Georgopoulos, N. A., Rousso, D. Diet, physical exercise and Orlistatadministration increase serum Anti-Mullerian Hormone (AMH) levels in womenwith polycystic ovary syndrome (PCOS)[J]. Gynecol Endocrinol,2013,29(3):242-245.
[10]Settas, N., Dracopoulou-Vabouli, M., Dastamani, A., et al. CYP21A2Mutationsin Women with Polycystic Ovary Syndrome (PCOS)[J]. Horm Metab Res,2013Feb5.[Epub ahead of print]
[11]Huang, G., Coviello, A. Clinical update on screening, diagnosis and managementof metabolic disorders and cardiovascular risk factors associated with polycysticovary syndrome [J]. Curr Opin Endocrinol Diabetes Obes,2012,19(6):512-519.
[12]Kahal, H., Aburima, A., Ungvari, T. Polycystic ovary syndrome has noindependent effect on vascular, inflammatory or thrombotic markers whenmatched for obesity [J]. Clin Endocrinol (Oxf),2012, doi:10.1111/cen.12137,[Epub ahead of print]
[13]Karoli, R., Fatima, J., Siddiqi, Z., et al. Study of early atherosclerotic markers inwomen with polycystic ovary syndrome [J]. Indian J Endocrinol Metab,2012,16(6):1004-1008.
[14]Neagu, M., Cristescu, C. Anti-Mullerian hormone--a prognostic marker formetformin therapy efficiency in the treatment of women with infertility andpolycystic ovary syndrome [J]. J Med Life,2012,5(4):462-464.
[15]Parahuleva, N., Pehlivanov, B., Dimitrakova, E., et al. Anti-Mullerian hormone-its role in the pathogenesis of the polycystic ovary syndrome [J]. Akush Ginekol(Sofiia),2012,51(6):22-26.
[16]Pawelczak, M., Kenigsberg, L., Milla, S., et al. Elevated serum anti-Mullerianhormone in adolescents with polycystic ovary syndrome: relationship toultrasound features [J]. J Pediatr Endocrinol Metab,2012,25(9-10):983-989.
[17]Macklon, N. S. Polycystic ovary syndrome [J]. BMJ,2011,343: d6407.
[18]Cakir, G. A., Erdogan, F. G., Gurler, A. Isotretinoin treatment in nodulocystic acnewith and without polycystic ovary syndrome: efficacy and determinants of relapse[J]. Int J Dermatol,2013,52(3):371-376.
[19]Gonzalez, F., Sia, C. L., Shepard, M. K., et al. Inflammation in response toglucose ingestion is independent of excess abdominal adiposity in normal-weightwomen with polycystic ovary syndrome [J]. J Clin Endocrinol Metab,2012,97(11):4071-4079.
[20]Mardanian, F., Heidari, N. Diagnostic value of prostate-specific antigen in womenwith polycystic ovary syndrome [J]. J Res Med Sci,2011,16(8):999-1005.
[21]Demir, B., Pasa, S., Demir, S., et al. Morphologic and functional vascularalterations in patients with polycystic ovary syndrome [J]. Clin Exp ObstetGynecol,2011,38(4):401-404.
[22] Bechtold, S., Dalla Pozza, R., Putzker, S., et al. Effect of antiandrogen treatmenton bone density and bone geometry in adolescents with polycystic ovarysyndrome [J]. J Pediatr Adolesc Gynecol,2012,25(3):175-180.
[23] Pradhan, A., Khalaf, H., Ochsner, S. A., et al. Activation of NF-kappaB proteinprevents the transition from juvenile ovary to testis and promotes ovariandevelopment in zebrafish [J]. J Biol Chem,2012,287(45):37926-37938.
[24] Dossi, F. C., Consoli, F. L. Ovarian development and analysis of mating effectson ovary maturation of Diaphorina citri Kuwayama (Hemiptera: Psyllidae)[J].Neotrop Entomol,2010,39(3):414-419.
[25] Dickinson, R. E., Hryhorskyj, L., Tremewan, H., et al. Involvement of theSLIT/ROBO pathway in follicle development in the fetal ovary [J]. Reproduction,2010,139(2):395-407.
[26] Gonzalez-Moran, M. G., Guzman, A. Effect of luteinizing hormone on the rightregressing ovary of newly hatched chicks treated during embryonic development[J]. Domest Anim Endocrinol,2012,43(1):58-66.
[27] Hummitzsch, K., Irving-Rodgers, H. F., Hatzirodos, N., et al. A new model ofdevelopment of the Mammalian ovary and follicles [J]. PLoS One,2013,8(2):e55578.
[28]Mlynarczuk, J., Rekawiecki, R. The role of the orphan receptor SF-1in thedevelopment and function of the ovary [J]. Reprod Biol,2010,10(3):177-193.
[29] Bu, Z., Kuok, K., Meng, J., et al. The relationship between polycystic ovarysyndrome, glucose tolerance status and serum preptin level [J]. Reprod BiolEndocrinol,2010,10:10.
[30]Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary [J]. BiolReprod,2008;78:380–389.
[31]Walters KA, Middlet on LJ, Joseph SR, Hazra R, Jimenez M, Simanainen U, et al.Targeted loss of androgen receptor signaling in murine granulosa cells ofpreantral and antral follicles causes female subfertility [J]. Biol Reprod,2012,87:151-162.
[32]Richards JS, Jahnse n T, Hedin L, Lifka J, Ratoosh SL, Du rica JM, Goldring NB.Ovarian follicular development: from physiology to molecular biology [J].Recent Prog Hormone Res,1987,43:231-276.
[33]Wickenheisser JK, Nels on-DeGrave VL, Hendri cks KL, Legro RS, Strauss JF,McAllister JM. Retinoids and retinol differentially regulate steroid biosynthesisin ovarian theca cells isolated from no rmal cycling women and women withpolycystic ovary syndrome [J]. J Clin Endocrinol Metab,2005;90:4858–65.
[34]Kezele PR, Ni lsson EE, Skinner MK. Insulin but not insulin-like growth factor-1promotes the primordial to primary follicle transition [J]. Mol Cell Endocrinol,2002,192:37-43.
[35] Altieri, P., Cavazza, C., Pasqui, F., et al. Dietary habits and their relationship withhormones and metabolism in overweight and obese women with polycystic ovarysyndrome [J]. Clin Endocrinol (Oxf),2013,78(1):52-59.
[36] Guzman, L., Ortega-Hrepich, C., Albuz, F. K., et al. Developmental capacity ofin vitro-matured human oocytes retrieved from polycystic ovary syndromeovaries containing no follicles larger than6mm [J]. Fertil Steril,2012,98(2):503-507e501-502.
[37]Santos, S. S., Ferreira, M. A., Pinto, J. A., et al. Characterization offolliculogenesis and the occurrence of apoptosis in the development of the bovinefetal ovary [J]. Theriogenology,2013,79(2):344-350.
[38] Chen, H., Palmer, J. S., Thiagarajan, R. D., et al. Identification of novel markersof mouse fetal ovary development [J]. PLoS One,2012,7(7): e41683.
[39] Somfai, T., Imai, K., Kaneda, M., et al. The effect of ovary storage and in vitromaturation on mRNA levels in bovine oocytes; a possible impact of maternalATP1A1on blastocyst development in slaughterhouse-derived oocytes [J]. JReprod Dev,2011,57(6):723-730.
[40] Stansfield, F. J., Nothling, J. O., Allen, W. R. Growth and development of theovary and small follicle pool from mid fetal life to pre-puberty in the Africanelephant (Loxodonta africana)[J]. BMC Vet Res,2012,8:119.
[41] Sopher, A. B., Gerken, A. T., Blaner, W. S., et al. Metabolic manifestations ofpolycystic ovary syndrome in nonobese adolescents: retinol-binding protein4andectopic fat deposition [J]. Fertil Steril,2012,97(4):1009-1015.
[42]Pellatt L, Rice S, Di laver N, Hes hri A, Galea R, Brinca t M, et al. Anti-mullerianhormone reduces follicle se nsitivity to follicle-stim ulating horm one in humangranu losa cells [J]. Fertil Steril,2011;96:1246–1251.
[43] Ott, J., Wattar, L., Kurz, C., et al."Parameters for calcium metabolism in womenwith polycystic ovary syndrome who undergo clomiphene citrate stimulation: aprospective cohort study [J]. Eur J Endocrinol,2012,166(5):897-902.
[44] Wang, C., Roy, S. K. Expression of bone morphogenetic protein receptor (BMPR)during perinatal ovary development and primordial follicle formation in thehamster: possible regulation by FSH[J]. Endocrinology,2009,150(4):1886-1896.
[45]Webber LJ, Stubbs SA, Stark J, Margara RA, Trew GH, Lavery SA, et al.Prolonged survival in culture of preantr al follicles from polycystic ovaries [J]. JClin Endocr inol Metab,2007;92:1975–1978.
[46]Gras, S., Georg, B., Jorgensen, H. L., Fahrenkrug, J. Expression of the clockgenes Per1and Bmal1during follicle development in the rat ovary. Effects ofgonadotropin stimulation and hypophysectomy [J]. Cell Tissue Res,2012,350(3):539-548.
[47] Kuwabara, Y., Katayama, A., Igarashi, T., et al. Rapid and transient upregulationof CCL11(eotaxin-1) in mouse ovary during terminal stages of folliculardevelopment [J]. Am J Reprod Immunol,2012,67(5):358-368.
[48] Garcia-Ortiz, J. E., Pelosi, E., Omari, S., et al. Foxl2functions in sexdetermination and histogenesis throughout mouse ovary development [J]. BMCDev Biol,2009,9:36.
[49]Pisarska MD, Barlow D, Huo FT. Minire view: Roles of the fork headtranscription fact or FOXL2in granulosa cell biology and pathology [J].Endocrinology,2011,152:1199-1208.
[50] Pisarska MD, Kuo FT, Tan g D, Zarrini P, Khan S, Ketefian A. Expression offorkhead transcription factors in human granulosa cells [J]. Fertil Steril,2009,91:1392–1394.
[51]Richards JS, Sha rma SC, Falender AE, Lo YH. Expr ession of FKHR, FKHRL1and AFX genes in the rodent ovar y: evidence for regulation by IGF-I, estrogenand the gonadotropins [J]. Mol Endocr inol,2002,16:580–599.
[52] Liu Z, Castrillon DH, Zhou W, Richards JS. FOXO1/3depletion in granulosecells alters follicle growth, death and regulation of pituitary FSH [J]. MolEndocrinol,2013,27:238–252.
[53]Strauss JF, Williams CJ. The ovarian life cycle [M]. In: Strauss JF, Barbieri RL,editors. Yen and Jaffe's reproductive endocrinology: physiology, patho-physiology,and clinical management.6th ed. Philadelphia: Saunders Elsevier,2009:155–190.
[54]Boyer A, Lapoin te E, Zheng X, Cowan RG, Quir k SM, DeMayo FJ, et al. WNT4is required for normal ovarian follicle development and female fertility [J].FASEB J,2010,24:3010–3025.
[55]Boyer A, Goff AK, Boerb oom D. WNT signaling in ovar ian follicle biology andtumorigenesis [J]. Trends Endocrinol Metab,2010,21:25–32.
[56]Fortes, P., Salvador, G., Consoli, F. L. Ovary development and maturation inNezara viridula (L.)(Hemiptera: Pentatomidae)[J]. Neotrop Entomol,2011,40(1):89-96.
[57]Vilmann, L. S., Thisted, E., Baker, J. L., Holm, J. C. Development of obesity andpolycystic ovary syndrome in adolescents [J]. Horm Res Paediatr,2012,78(5-6):269-278.
[58]Gonzalez, F., Kirwan, J. P., Rote, N. S., Minium, J. Elevated circulating levels oftissue factor in polycystic ovary syndrome [J]. Clin Appl Thromb Hemost,2013,19(1):66-72.
[59]Legro, R. S., Kunselman, A. R., Brzyski, R. G., et al. The Pregnancy in PolycysticOvary Syndrome II (PPCOS II) trial: rationale and design of a double-blindrandomized trial of clomiphene citrate and letrozole for the treatment of infertilityin women with polycystic ovary syndrome [J]. Contemp Clin Trials,2012,33(3):470-481.
[60]Aleyasin, A., Aghahoseini, M., Mokhtar, S., Fallahi, P. Anti-mullerian hormone asa predictive factor in assisted reproductive technique of polycystic ovarysyndrome patients [J]. Acta Med Iran,2011,49(11):715-720.
[61]Mashiach, R., Amit, A., Hasson, J., et al. Follicular fluid levels of anti-Mullerianhormone as a predictor of oocyte maturation, fertilization rate, and embryonicdevelopment in patients with polycystic ovary syndrome [J]. Fertil Steril,2010,93(7):2299-2302.
[62]Kawai, T., Mihara, T., Kawashima, I., et al. Endogenous acetaldehyde toxicityduring antral follicular development in the mouse ovary [J]. Reprod Toxicol,2012,33(3):322-330.
[63]McGee WK, Bishop CV, Bahar A, Pohl CR, Ch ang RJ, Marshall JC, et al.Elevated androgens during puberty in female rhesus monkeys lead to increasedneuronal drive to the reproductive axis: a possible component of polycystic ovarysyndrome [J]. Hum Reprod,2012,27:531-540.
[64]Roland AV, Moenter SM. Prenatal andro genization of female mice programs anincrease infiring activity of gonadotropin-releasing hormone (GnRH) neuronsthat is reversed by metformin treatment in adulthood [J]. Endocrinology,2011,152:618-628.
[65]Garverick, H. A., Juengel, J. L., Smith, P., et al. Development of the ovary andontongeny of mRNA and protein for P450aromatase(arom) and estrogenreceptors (ER) alpha and beta during early fetal life in cattle [J]. Anim Reprod Sci117(1-2):24-33.
[66]Kenigsberg S, Bentov Y, Chalifa-Caspi V, et al. Gene expression microarrayprofiles of cumulus cells in lean and overweight-obese polycystic ovarysyndrome patients [J]. Mol Hum Reprod,2009,15:89-103.
[67]El-Khairi, R., Parnaik, R., Duncan, A. J., et al. Analysis of LIN28A in earlyhuman ovary development and as a candidate gene for primary ovarianinsufficiency [J]. Mol Cell Endocrinol,2012,351(2):264-268.
[68]Da Silva-Buttkus, P., Jayasooriya, G. S., Mora, J. M., et al. Effect of cell shapeand packing density on granulosa cell proliferation and formation of multiplelayers during early follicle development in the ovary [J]. J Cell Sci,2008,121(Pt23):3890-3900.
[69]Zeleznik AJ, Little-Ihrig L, Ramas awamy S. Administrat ion of dihydrotestosterone to rhesus monkeys inhibits gonadotropin-stimulated ovariansteroidogenesis [J]. J Cl in Endocrinol Metab,2004:89:860–866.
[70]Pradeep PK, Li X, Peegel H, Menon KM. Dihydrot estosterone inhibits granulosacell proliferation by decreasing the cyclin D2mRNA expression and cell cyclearrest at G1phase [J]. Endocrinology,2002,143:2930–935.
[71]Borisov, O. V., Field, M., Ling, V. T., Harris, R. J. Characterization ofoligosaccharides in recombinant tissue plasminogen activator produced inChinese hamster ovary cells: two decades of analytical technology development[J]. Anal Chem,2009,81(23):9744-9754.
[72]Duarte, A. B., Araujo, V. R., Chaves, R. N., et al. Insulin-like growth factor II(IGF-II) and follicle stimulating hormone (FSH) combinations can improve the invitro development of grown oocytes enclosed in caprine preantral follicles [J].Growth Horm IGF Res,2013,23(1-2):37-44.
[73]Ichikawa, C., Izawa, T., Juniantito, V., et al. Rat hair follicle-constituting cellslabeled by a newly-developed somatic stem cell-recognizing antibody: a possiblemarker of hair follicle development [J]. Histol Histopathol,2013,28(2):257-268.
[74]Frota, I. M., Leitao, C. C., Costa, J. J., et al. Levels of BMP-6mRNA in goatovarian follicles and in vitro effects of BMP-6on secondary follicle development[J]. Zygote,2011,1-9.
[75]Dumesic DA, Lesnick TG, Stassart JP, Ball GD, Wong A, Abbott DH.Intrafollicular antimullerian hormone levels predict follicle responsiveness tofollicle-stimulating hormone (FSH) in normoandrogenic ovulatory womenundergoing gonadotropin releasing-hormone analog/recombinant human FSHtherapy for in vitro fertilization and embryo transfer [J]. Fertil Steril,2009,92:217-221.
[76]Palma, G. A., Arganaraz, M. E., Barrera, A. D., et al. Biology and biotechnologyof follicle development [J]. Scientific World Journal,2012:938138.
[77]Dilaver NM, Goes D, Rice S, Mason HD. Anti-mullerian hormone may contributeto anovulation in PCOS via inhibition of human granulosa cell growth [A].Presented at the94th Annual Meeting of the Endocr ine Society [C]; June23–26,2012; Houston, TX; abstract: MON-18.
[78]Catteau-Jonard S, Jamin SP, Leclerc A, Gonzal" es J, Dewa illy D, di Clemente N.Anti-mullerian hormone, its receptor, FSH receptor, and androgen receptor genesare over expressed by granulosa cells from stimulated follicles in women withpolycystic ovary syndrome [J]. J Clin Endocrinol Metab,2008,93:4456–4461.
[79]Panidis D, Kats ikis I, Karkana ki A, Piouk a A, Arm eni AK, Ge orgopoulos NA.Serum anti-mullerian hormone (AMH) levels are differentially modulated by bothserum gonadotropins and not only by serum follicle stimulating hormone (FSH)levels [J]. Med Hypotheses,2011,77:649–653.
[80]Thomson RL, B uckley JD, Moran LJ, Noak es M, Clifton PM, Norman RJ,Brinkworth GD. The effect of weight loss on anti-mullerian hormone levels inoverweight and obese women with polycystic ovary syndrome and reproductiveimpairment [J]. Hum Reprod,2009,24:1976-1981.
[81]Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzo ne A, Guido M. Themetabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome [J].J Clin Endocrinol Metab,2011,96: E821–E824.
[82]Knight PG, Glister C. Potential local regulatory functions of inhibins, activins andfollistatin in the ovary [J]. Reproduction,2001,121:503-512.
[83]Gold, E., Marino, F. E., Harrison, C., et al. Activin-beta(c) reduces reproductivetumour progression and abolishes cancer-associated cachexia in inhibin-deficientmice [J]. J Pathol,2013,229(4):599-607.
[84]Winnall, W. R., Wu, H., Sarraj, M. A., et al. Expression patterns of activin, inhibinand follistatin variants in the adult male mouse reproductive tract suggestimportant roles in the epididymis and vas deferens [J]. Reprod Fertil Dev25(3):570-580.
[85]Lee, Y., Jung, J., Cho, K. J., et al. Increased SCF/c-kit by hypoxia promotesautophagy of human placental chorionic plate-derived mesenchymal stem cellsvia regulating the phosphorylation of mTOR. J Cell Biochem [J],2013,114(1):79-88.
[86]Jin, Q. H., Shen, H. X., Wang, H., et al. Curcumin improves expression ofSCF/c-kit through attenuating oxidative stress and NF-kappaB activation ingastric tissues of diabetic gastroparesis rats [J]. Diabetol Metab Syndr,2013,5(1):12.
[87]Li, S., Park, H., Trempus, C. S., et al. A keratin15containing stem cell populationfrom the hair follicle contributes to squamous papilloma development in themouse [J]. Mol Carcinog,2012, doi:10.1002/mc.21896.[Epub ahead of print]
[88]Phelan, N., O'Connor, A., Kyaw Tun, T., et al. Leucocytosis in women withpolycystic ovary syndrome (PCOS) is incompletely explained by obesity andinsulin resistance [J]. Clin Endocrinol (Oxf),2013,78(1):107-113.
[89]Flannery, C. A., Rackow, B., Cong, X., et al. Polycystic ovary syndrome inadolescence: impaired glucose tolerance occurs across the spectrum of BMI [J].Pediatr Diabetes,2013,14(1):42-49.
[90]Yildiz, B. O., Bozdag, G., Yapici, Z., et al. Prevalence, phenotype andcardiometabolic risk of polycystic ovary syndrome under different diagnosticcriteria [J]. Hum Reprod,2012,27(10):3067-3073.
[91]Sir-Petermann T, Codner E, Perez V, et al. Metabolic and reproductive featuresbefore and during puberty in daughters of women with polycystic ovarysyndrome [J]. J Clin Endocrinol Metab,2009,94:1923-1930.
[2] Robert A. Wild, Manfredi Rizzo, Sheri Clifton, et al. Lipid levels in polycysticovary syndrome: systematic review and meta-analysis [J]. Fertility and Sterility,2011,95(3):1073-1079.
[3] Lisa J. Moran, Boyd J. Strauss, Helena J. Teede. Diabetes risk score in thediagnostic categories of polycystic ovary syndrome [J]. Fertility and Sterility,2011, doi:10.1016/j.fertnstert.2011.01.133.
[4] Gautam N. Allahbadia, Rubina Merchant. Polycystic ovary syndrome and impacton health [J]. Middle East Fertility Society Journal,2011,16:19–37.
[5] The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.Revised2003consensus on diagnostic criteria and long-term health risks relatedto polycystic ovary syndrome (PCOS)[J]. Human Reproduction,2004,19(1):41-47.
[6] March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: Theprevalence of polycystic ovary syndrome in a community sample assessed undercontrasting diagnostic criteria [J]. Hum Reprod,2010,25:544-551.
[7] Mahesh, V. B. Hirsutism, virilism, polycystic ovarian disease, and thesteroid-gonadotropin-feedback system: a career retrospective [J]. Am J PhysiolEndocrinol Metab,2012,302(1): E4-E18.
[8]王增杰，王秀霞.辽宁省汉族育龄妇女多囊卵巢综合征患病情况的流行病学调查[M].中国医科大学硕士学位论文，2009:1-5.
[9]赵君利,陈子江.多囊卵巢综合征的流行病学调查及相关基础研究[M].山东大学博士学位论文，2006:1-3.
[10]陈红,宋学茹.天津地区育龄期妇女多囊卵巢综合征临床特征及发病相关因素的流行病学调查研究[M].天津医科大学硕士学位论文，2009:1-3.
[11]Sathyapalan, T., Atkin, S. L. Recent advances in cardiovascular aspects ofpolycystic ovary syndrome [J]. Eur J Endocrinol,2012,166(4):575-583.
[12]Tamara Baer, Amy DiVasta. A longitudinal comparison of cardiovascular riskfactors in overweight and normal-weight adolescents with polycyctic ovarysyndrome (PCOS)[J]. Poster Abstracts,2011,48: S19.
[13]De Groot PC, Dekkers OM, Romijn JA, et al. Hum. Reprod [J]. Update,2011, doi:10.1093/humupd/dmr001.
[14]Mahesh, V. B. Hirsutism, virilism, polycystic ovarian disease, and thesteroid-gonadotropin-feedback system: a career retrospective [J]. Am J PhysiolEndocrinol Metab,2012,302(1): E4-E18.
[15]Bulent O. Yildiz, Ricardo Azziz. Ovarian and adipose tissue dysfunction inpolycystic ovary syndrome: report of the4th special scientific meeting of theAndrogen Excess and PCOS Society [J]. Fertility and Sterility,2010,94(2):690-693.
[16]Berstein, L. M. Metformin in obesity, cancer and aging: addressing controversies[J]. Aging (Albany NY),2012,4(5):320-329.
[17]Konstantinos G. Michalakis, James H. Segars. The role of adiponectin inreproduction: from polycystic ovary syndrome to assisted reproduction [J].Fertility and Sterility,2010,94(6):1949-1957.
[18]Andrea Repaci, Alessandra Gambineri, Renato Pasquali. The role of low-gradeinflammation in the polycystic ovary syndrome [J]. Mol. Cell. Endocrinol,2010,doi:10.1016/j.mce.2010.08.002.
[19]Matthew C. Ernst, Christopher J. Sinal. Chemerin: at the crossroads ofinflammation and obesity [J]. Trends in Endocrinology and Metabolism,2010,21(11):660-667.
[20]Bowen Jiang, Heather A. Kenna, Natalie L. Rasgon. Genetic overlap betweenpolycystic ovary syndrome and bipolar disorder: The endophenotype hypothesis[J]. Medical Hypotheses,2009,73:996–1004.
[21]郭海燕,赵晓明,高敏芝.多囊卵巢综合征与相关基因多态性的研究进展[J].生殖与避孕,2009,29(5):319-323.
[22]Anastasios Ioannidis, Eleni Ikonomi, Niki L. Dimou. Polymorphisms of theinsulin receptor and the insulin receptor substrates genes in polycystic ovarysyndrome: A Mendelian randomization meta-analysis [J]. Molecular Genetics andMetabolism,2010,99:174–183.
[23]Catherine G. Baptiste, Marie-Claude Battista, Andréanne Trottier, te al. Insulinand hyperandrogenism in women with polycystic ovary syndrome [J]. Journal ofSteroid Biochemistry&Molecular Biology,2010,122:42–52.
[24]Thozhukat Sathyapalan, Stephen L. Atkin. Mediators of Inflammation inPolycystic Ovary Syndrome in Relation to Adiposity [J]. Mediators ofInflammation,2010:1-5. doi:10.1155/2010/758656.
[25]Burt Solorzano, C. M. Beller, J. P. Abshire, M. Y., et al. Neuroendocrinedysfunction in polycystic ovary syndrome [J]. Steroids,2012,77(4):332-337.
[26]Walton, K. L., Makanji, Y., Harrison, C. A. New insights into the mechanisms ofactivin action and inhibition [J]. Mol Cell Endocrinol,2012,359(1-2):2-12.
[27]Lotinun, S., Pearsall, R. S., Horne, W. C., Baron, R. Activin receptor signaling: apotential therapeutic target for osteoporosis [J]. Curr Mol Pharmacol,2012,5(2):195-204.
[28]Shelling, A. N. Mutations in inhibin and activin genes associated with humandisease [J]. Mol Cell Endocrinol,2012,359(1-2):113-120.
[29]Norman, R. J., Milner, C. R., Groome, N. P., and Robertson, D. M. Circulatingfollistatin concentrations are higher and activin concentrations are lower inpolycystic ovarian syndrome [J]. Hum Reprod2001;16(4):668-672.
[30]de Kretser, D. M., O'Hehir, R. E., Hardy, C. L., Hedger, M. P. The roles of activinA and its binding protein, follistatin, in inflammation and tissue repair [J]. MolCell Endocrinol,2012,359(1-2):101-106.
[31]Payne, C., King, J., Hay, D. The role of activin/nodal and Wnt signaling inendoderm formation [J]. Vitam Horm,2011,85:207-216.
[1] David Escors, Karine Breckpot. Lentiviral vectors in gene therapy: their currentstatus and future potential [J]. Arch Immunol Ther Exp (Warsz),2010,58(2):107–119. doi:10.1007/s00005-010-0063-4.
[2] David V. Schaffer, James T. Koerber, and Kwang-il Lim. Molecular Engineeringof Viral Gene Delivery Vehicles [J]. Annu Rev Biomed Eng,2008,10:169–194.doi:10.1146/annurev.bioeng.10.061807.160514.
[3] Eun Young Kim, Young Bin Hong and Zhennan Lai, et al. Expression andsecretion of human glucocerebrosidase mediated by recombinant lentivirusvectors in vitro and in vivo: implications for gene therapy of Gaucher disease [J].Biochemical and Biophysical Research Communications,2004,318:381–390.
[4] Qin Hua, Chunhua Chena and Nikan H. Khatibi, et al. Lentivirus-mediatedtransfer of MMP-9shRNA provides neuroprotection following focal ischemicbrain injury in rats [J]. BRAIN RESEARCH,2011,1367:347–359.
[5] Sakuma, T., Barry, M. A., Ikeda, Y. Lentiviral vectors: basic to translational [J].Biochem J,2012,443(3):603-618.
[6] Rossetti, M., Cavarelli, M., Gregori, S., Scarlatti, G. HIV-derived vectors for genetherapy targeting dendritic cells [J]. Adv Exp Med Biol,2013,762:239-261.
[7] Picanco-Castro, V., de Sousa Russo-Carbolante, E. M., Tadeu Covas, D. Advancesin lentiviral vectors: a patent review [J]. Recent Pat DNA Gene Seq,2012,6(2):82-90.
[8] Mantovani J, Charrier S, Eckenberg R, Saurin W, Danos O, Perea J, Galy A.Diverse genomic integration of a lentiviral vector developed for the treatment ofWiskott-Aldrich syndrome [J]. J Gene Med,2009,11(8):645-654.
[9] Peter C. Huszthy, Tsanan Giroglou and Oleg Tsinkalovsky, et al. Remission ofInvasive, Cancer Stem-Like Glioblastoma Xenografts Using LentiviralVector-Mediated Suicide Gene Therapy [J]. PLoS One,2009,4(7): e6314.
[10]Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy andsafety of gene therapy for Wiskott-Aldrich syndrome in preclinical models [J].Molecular Therapy,2009,17:1073–1082.[PubMed:19259069]
[11]Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy:targeting activation pathways through genetic modification [J]. EMID-DT,2009,9(4):328-43.
[12]VB O’Leary, SV Ovsepian and A Raghunath, et al. Innocuous full-lengthbotulinum neurotoxin targets and promotes the expression of lentiviral vectors incentral and autonomic neurons [J]. Gene Therapy,2011,18:656–665.
[13] Roth, S. D., Schuttrumpf, J., Milanov, P., Abriss, D., Ungerer, C., Quade-Lyssy,P., Simpson, J. C., Pepperkok, R., Seifried, E., Tonn, T. Chemical chaperonesimprove protein secretion and rescue mutant factor VIII in mice with hemophiliaA [J]. PLoS One,2012,7(9): e44505.
[14]李红,曾卫森,罗琛,等. Bax/Bak在抑制人颗粒细胞凋亡中的作用[J].南方医科大学学报,2009,29(12):2367-2370.
[15]Gautam N. Allahbadia and Rubina Merchant. Polycystic ovary syndrome andimpact on health [J]. Middle East Fertil Soc J,2010, doi:10.1016/j.mefs.2010.10.002.
[1] Sven Ansorge, Olivier Henry, Amine Kamen. Recent progress in lentiviral vectormass production [J]. Biochemical Engineering Journal,2010,48:362–377.
[2] Smed-Sorensen, A., Lore, K. Targeting dendritic cells for improved HIV-1vaccines [J]. Adv Exp Med Biol,2013,762:263-288.
[3] Primo, M. N., Bak, R. O., Mikkelsen, J. G. Lentiviral vectors for cutaneous RNAmanaging [J]. Exp Dermatol,2012,21(3):162-170.
[4] Warnock, J. N., Daigre, C., Al-Rubeai, M. Introduction to viral vectors [J].Methods Mol Biol,2011,737:1-25.
[5] Di Nunzio, F., Felix, T., Arhel, N. J., Nisole, S., Charneau, P., Beignon, A. S.HIV-derived vectors for therapy and vaccination against HIV [J]. Vaccine,2012,30(15):2499-2509.
[6] Ruiz, M., Deglon, N. Viral-mediated overexpression of mutant huntingtin tomodel HD in various species [J]. Neurobiol Dis,2012,48(2):202-211.
[7] Durand, S., Cimarelli, A. The inside out of lentiviral vectors [J]. Viruses,2011,3(2):132-159.
[8] Rao, M. S., Malik, N. Assessing iPSC reprogramming methods for their suitabilityin translational medicine [J]. J Cell Biochem,2012,113(10):3061-3068.
[9] Mochiduki, Y., Okita, K. Methods for iPS cell generation for basic research andclinical applications [J]. Biotechnol J,2012,7(6):789-797.
[10] Hirai, H. Basic research on cerebellar gene therapy using lentiviral vectors [J].Cerebellum,2012,11(2):443-445.
[1] Kosova, G., Urbanek, M. Genetics of the polycystic ovary syndrome [J].Molecular and Cellular Endocrinology (2012), http://dx.doi.org/10.1016/j.mce.2012.10.009
[2] Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., Azziz, R. Polycystic ovarysyndrome: etiology, pathogenesis and diagnosis [J]. Nat Rev Endocrinol,2011,7(4):219-231.
[3] Christine M. Burt Solorzano, Jennifer P. Beller, Michelle Y. Abshire, Jessicah S.Collins, Christopher R. McCartney, John C. Marshall. Neuroendocrinedysfunction in polycystic ovary syndrome [J]. Steroids,2012,77:332–337.
[4] Cruz, G., Barra, R., Gonzalez, D., Sotomayor-Zarate, R., Lara, H. E. Temporalwindow in which exposure to estradiol permanently modifies ovarian functioncausing polycystic ovary morphology in rats [J]. Fertil Steril,2012,98(5):1283-1290.
[5] Shi, D., Vine, D. F. Animal models of polycystic ovary syndrome: a focusedreview of rodent models in relationship to clinical phenotypes andcardiometabolic risk [J]. Fertil Steril,2012,98(1):185-193.
[6] Walters, K. A., Allan, C. M., Handelsman, D. J. Rodent models for humanpolycystic ovary syndrome [J]. Biol Reprod,2012,86(5):149,141-112.
[7] Miyazono, K., Kamiya, Y., Morikawa, M.. Bone morphogenetic protein receptorsand signal transduction [J]. J. Biochem,2010,147:35–51.
[8] Phil G. Knight, Leanne Satchell, Claire Glister. Intra-ovarian roles of activins andinhibins [J]. Molecular and Cellular Endocrinology,2012,359:53–65.
[9] Xia, Y., Schneyer, A. L. The biology of activin: recent advances in structure,regulation and function [J]. J Endocrinol,2009,202(1):1-12.
[10]McLaughlin, M., Bromfield, J. J., Albertini, D. F., Telfer, E. E. Activin promotesfollicular integrity and oogenesis in cultured pre-antral bovine follicles [J]. MolHum Reprod,2010,16(9):644-653.
[11]Thomas, F. H., Armstrong, D. G., Telfer, E. E. Activin promotes oocytedevelopment in ovine preantral follicles in vitro [J]. Reprod Biol Endocrinol,2003,1:76.
[12]Zhao, J., Taverne, M. A., van der Weijden, G. C., Bevers, M. M., van den Hurk, R.Effect of activin A on in vitro development of rat preantral follicles andlocalization of activin A and activin receptor II [J]. Biol Reprod,2001,65(3):967-977.
[13]Kipp, J. L., Kilen, S. M., Woodruff, T. K., Mayo, K. E. Activin regulates estrogenreceptor gene expression in the mouse ovary [J]. J Biol Chem,2007,282(50):36755-36765.
[14]Xia, Y., Schneyer, A. L. The biology of activin: recent advances in structure,regulation and function [J]. J Endocrinol,2009,202(1):1-12.
[15]Christopher A. Pearl, Holly Mason, Janet F. Roser. Immunolocalization ofestrogen receptor alpha, estrogen receptor beta and androgen receptor in the pre-,peri-and post-pubertal stallion testis [J]. Animal Reproduction Science,2011,125:103–111.
[16]Douglas A. Gibson, Philippa T.K. Saunders. Estrogen dependent signaling inreproductive tissues–A role for estrogen receptors and estrogen related receptors[J]. Molecular and Cellular Endocrinology,2012,348:361–372.
[17]Renoir, J. M., Marsaud, V., Lazennec, G. Estrogen receptor signaling as a targetfor novel breast cancer therapeutics [J]. Biochem Pharmacol,2013,85(4):449-465.
[1] Wongbandue, G., Jewgenow, K., Chatdarong, K. Effects of thyroxin (T(4)) andactivin A on in vitro growth of preantral follicles in domestic cats [J].Theriogenology,2012,79(5):824-832.
[2] Hofland, J., van Weerden, W. M., Steenbergen, J., Dits, N. F., Jenster, G., de Jong,F. H. Activin A stimulates AKR1C3expression and growth in human prostatecancer [J]. Endocrinology,2012,153(12):5726-5734.
[3] Roberts-Galbraith, R. H., Newmark, P. A. Follistatin antagonizes Activin signalingand acts with Notum to direct planarian head regeneration [J]. Proc Natl Acad SciUSA,2013,110(4):1363-1368.
[4] Mathew, S., Jaramillo, M.,Zhang, X., Zhang, L. A., Soto-Gutierrez, A., Banerjee, I.Analysis of alternative signaling pathways of endoderm induction of humanembryonic stem cells identifies context specific differences [J]. BMC Syst Biol,2012,6:154.
[5] Dong Huansheng, Pan Qingjie, Zhang Hanqiong, Zhang Lianjun, Chen Bo, YueWenbin. Estrogen inhibits the early development of mouse follicles throughregulating the expression of Kit ligand [J]. Biochemical and BiophysicalResearch Communications,2011,410:659–664.
[6] Lennartsson, J., and Ronnstrand, L. Stem cell factor receptor/c-Kit: from basicscience to clinical implications [J]. Physiol Rev,2012,92(4):1619-1649.
[7] Daniel A. Dumesic, JoAnne S. Richards. Ontogeny of the ovary in polycysticovary syndrome [J]. Fertility and Sterility,2013, http://dx.d oi.org/10.1016/j.fertnstert.2013.02.011.
[8] Zapater, C., Chauvigne, F., Tingaud-Sequeira, A., Finn, R. N., Cerda, J. Geneticmanipulation of keratinocyte stem cells with lentiviral vectors [J]. Methods MolBiol,2013,989:143-151.
[9] Hennet, M. L., Combelles, C. M. The antral follicle: a microenvironment foroocyte differentiation [J]. Int J Dev Biol,2012,56(10-11-12):819-831.
[10]Rosenbusch, B. The potential significance of binovular follicles and binucleategiant oocytes for the development of genetic abnormalities [J]. J Genet,2012,91(3):397-404.
[11]Beresford, D. V., Sutcliffe, J. F. Field measurements of stable fly (Diptera:Muscidae) demography, fecundity, and survival based on daily trap catches at abeef farm in southern Ontario over a5-yr period [J]. J Med Entomol,2012,49(6):1262-1269.
[12]Barros, C. M., Satrapa, R. A., Castilho, A. C., Fontes, P. K., Razza, E. M., Ereno,R. L., Nogueira, M. F. Effect of superstimulatory treatments on the expression ofgenes related to ovulatory capacity, oocyte competence and embryo developmentin cattle [J]. Reprod Fertil Dev,2012,25(1):17-25.
[13] Pan, T. L., Wang, P. W. Explore the Molecular Mechanism of Apoptosis Inducedby Tanshinone IIA on Activated Rat Hepatic Stellate Cells [J]. Evid BasedComplement Alternat Med,2012:734987.
[14] Maekawa, T. Cell-cycle regulators as molecular target [J]. Nihon Rinsho,2012,70Suppl8:119-124.
[15]I.M.T. Lima, I.R. Brito, G.Q. Rodrigues, et al. Presence of c-kit mRNA in goatovaries and improvement ofin vitro preantral follicle survival and developmentwith kit ligand [J]. Molecular and Cellular Endocrinology,2011,345:38–47.
[16]Janson, C., Kasahara, N., Prendergast, G. C., Colicelli, J. RIN3is a negativeregulator of mast cell responses to SCF [J]. PLoS One,2012,7(11): e49615.
[17]Ouni, I., Flick, K., Kaiser, P. A transcriptional activator is part of an SCF ubiquitinligase to control degradation of its cofactors [J]. Mol Cell,2010,40(6):954-964.
[18]Guglielmo, M. C., Ricci, G., Catizone, A., et al. The effect of hepatocyte growthfactor on the initial stages of mouse follicle development [J]. J Cell Physiol,2011,226(2):520-529.
[1] Stepto, N. K., Cassar, S., Joham, A. E., et al. Women with polycystic ovarysyndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemicclamp [J]. Hum Reprod,2013,28(3):777-784.
[2] Ravn, P., Haugen, A. G., Glintborg, D. Overweight in polycystic ovary syndrome.An update on evidence based advice on diet, exercise and metformin use forweight loss [J]. Minerva Endocrinol,2013,38(1):59-76.
[3] Sir-Petermann, T., Ladron de Guevara, A., Villarroel, A. C., et al. Polycystic ovarysyndrome and pregnancy [J]. Rev Med Chil,2012,140(7):919-925.
[4] Saxena, P., Prakash, A., Nigam, A., et al. Polycystic ovary syndrome: Is obesity asine qua non? A clinical, hormonal, and metabolic assessment in relation to bodymass index [J]. Indian J Endocrinol Metab,2012,16(6):996-999.
[5] Kosova, G., Urbanek, M. Genetics of the polycystic ovary syndrome [J]. Mol CellEndocrinol,2012. doi:10.1016/j.mce.2012.10.009.[Epub ahead of print]
[6] Pangaribuan, B., Yusuf, I., Mansyur, M., Wijaya, A. Serum adiponectin andresistin in relation to insulin resistance and markers of hyperandrogenism in leanand obese women with polycystic ovary syndrome [J]. Ther Adv EndocrinolMetab,2011,2(6):235-245.
[7] Barber, T. M., Franks, S. Adipocyte biology in polycystic ovary syndrome [J]. MolCell Endocrinol,2012, doi:10.1016/j.mce.2012.10.010.[Epub ahead of print]
[8] Diamanti-Kandarakis, E., Dunaif, A. Insulin resistance and the polycystic ovarysyndrome revisited: an update on mechanisms and implications [J]. Endocr Rev,2012,33(6):981-1030.
[9] Vosnakis, C., Georgopoulos, N. A., Rousso, D. Diet, physical exercise and Orlistatadministration increase serum Anti-Mullerian Hormone (AMH) levels in womenwith polycystic ovary syndrome (PCOS)[J]. Gynecol Endocrinol,2013,29(3):242-245.
[10]Settas, N., Dracopoulou-Vabouli, M., Dastamani, A., et al. CYP21A2Mutationsin Women with Polycystic Ovary Syndrome (PCOS)[J]. Horm Metab Res,2013Feb5.[Epub ahead of print]
[11]Huang, G., Coviello, A. Clinical update on screening, diagnosis and managementof metabolic disorders and cardiovascular risk factors associated with polycysticovary syndrome [J]. Curr Opin Endocrinol Diabetes Obes,2012,19(6):512-519.
[12]Kahal, H., Aburima, A., Ungvari, T. Polycystic ovary syndrome has noindependent effect on vascular, inflammatory or thrombotic markers whenmatched for obesity [J]. Clin Endocrinol (Oxf),2012, doi:10.1111/cen.12137,[Epub ahead of print]
[13]Karoli, R., Fatima, J., Siddiqi, Z., et al. Study of early atherosclerotic markers inwomen with polycystic ovary syndrome [J]. Indian J Endocrinol Metab,2012,16(6):1004-1008.
[14]Neagu, M., Cristescu, C. Anti-Mullerian hormone--a prognostic marker formetformin therapy efficiency in the treatment of women with infertility andpolycystic ovary syndrome [J]. J Med Life,2012,5(4):462-464.
[15]Parahuleva, N., Pehlivanov, B., Dimitrakova, E., et al. Anti-Mullerian hormone-its role in the pathogenesis of the polycystic ovary syndrome [J]. Akush Ginekol(Sofiia),2012,51(6):22-26.
[16]Pawelczak, M., Kenigsberg, L., Milla, S., et al. Elevated serum anti-Mullerianhormone in adolescents with polycystic ovary syndrome: relationship toultrasound features [J]. J Pediatr Endocrinol Metab,2012,25(9-10):983-989.
[17]Macklon, N. S. Polycystic ovary syndrome [J]. BMJ,2011,343: d6407.
[18]Cakir, G. A., Erdogan, F. G., Gurler, A. Isotretinoin treatment in nodulocystic acnewith and without polycystic ovary syndrome: efficacy and determinants of relapse[J]. Int J Dermatol,2013,52(3):371-376.
[19]Gonzalez, F., Sia, C. L., Shepard, M. K., et al. Inflammation in response toglucose ingestion is independent of excess abdominal adiposity in normal-weightwomen with polycystic ovary syndrome [J]. J Clin Endocrinol Metab,2012,97(11):4071-4079.
[20]Mardanian, F., Heidari, N. Diagnostic value of prostate-specific antigen in womenwith polycystic ovary syndrome [J]. J Res Med Sci,2011,16(8):999-1005.
[21]Demir, B., Pasa, S., Demir, S., et al. Morphologic and functional vascularalterations in patients with polycystic ovary syndrome [J]. Clin Exp ObstetGynecol,2011,38(4):401-404.
[22] Bechtold, S., Dalla Pozza, R., Putzker, S., et al. Effect of antiandrogen treatmenton bone density and bone geometry in adolescents with polycystic ovarysyndrome [J]. J Pediatr Adolesc Gynecol,2012,25(3):175-180.
[23] Pradhan, A., Khalaf, H., Ochsner, S. A., et al. Activation of NF-kappaB proteinprevents the transition from juvenile ovary to testis and promotes ovariandevelopment in zebrafish [J]. J Biol Chem,2012,287(45):37926-37938.
[24] Dossi, F. C., Consoli, F. L. Ovarian development and analysis of mating effectson ovary maturation of Diaphorina citri Kuwayama (Hemiptera: Psyllidae)[J].Neotrop Entomol,2010,39(3):414-419.
[25] Dickinson, R. E., Hryhorskyj, L., Tremewan, H., et al. Involvement of theSLIT/ROBO pathway in follicle development in the fetal ovary [J]. Reproduction,2010,139(2):395-407.
[26] Gonzalez-Moran, M. G., Guzman, A. Effect of luteinizing hormone on the rightregressing ovary of newly hatched chicks treated during embryonic development[J]. Domest Anim Endocrinol,2012,43(1):58-66.
[27] Hummitzsch, K., Irving-Rodgers, H. F., Hatzirodos, N., et al. A new model ofdevelopment of the Mammalian ovary and follicles [J]. PLoS One,2013,8(2):e55578.
[28]Mlynarczuk, J., Rekawiecki, R. The role of the orphan receptor SF-1in thedevelopment and function of the ovary [J]. Reprod Biol,2010,10(3):177-193.
[29] Bu, Z., Kuok, K., Meng, J., et al. The relationship between polycystic ovarysyndrome, glucose tolerance status and serum preptin level [J]. Reprod BiolEndocrinol,2010,10:10.
[30]Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary [J]. BiolReprod,2008;78:380–389.
[31]Walters KA, Middlet on LJ, Joseph SR, Hazra R, Jimenez M, Simanainen U, et al.Targeted loss of androgen receptor signaling in murine granulosa cells ofpreantral and antral follicles causes female subfertility [J]. Biol Reprod,2012,87:151-162.
[32]Richards JS, Jahnse n T, Hedin L, Lifka J, Ratoosh SL, Du rica JM, Goldring NB.Ovarian follicular development: from physiology to molecular biology [J].Recent Prog Hormone Res,1987,43:231-276.
[33]Wickenheisser JK, Nels on-DeGrave VL, Hendri cks KL, Legro RS, Strauss JF,McAllister JM. Retinoids and retinol differentially regulate steroid biosynthesisin ovarian theca cells isolated from no rmal cycling women and women withpolycystic ovary syndrome [J]. J Clin Endocrinol Metab,2005;90:4858–65.
[34]Kezele PR, Ni lsson EE, Skinner MK. Insulin but not insulin-like growth factor-1promotes the primordial to primary follicle transition [J]. Mol Cell Endocrinol,2002,192:37-43.
[35] Altieri, P., Cavazza, C., Pasqui, F., et al. Dietary habits and their relationship withhormones and metabolism in overweight and obese women with polycystic ovarysyndrome [J]. Clin Endocrinol (Oxf),2013,78(1):52-59.
[36] Guzman, L., Ortega-Hrepich, C., Albuz, F. K., et al. Developmental capacity ofin vitro-matured human oocytes retrieved from polycystic ovary syndromeovaries containing no follicles larger than6mm [J]. Fertil Steril,2012,98(2):503-507e501-502.
[37]Santos, S. S., Ferreira, M. A., Pinto, J. A., et al. Characterization offolliculogenesis and the occurrence of apoptosis in the development of the bovinefetal ovary [J]. Theriogenology,2013,79(2):344-350.
[38] Chen, H., Palmer, J. S., Thiagarajan, R. D., et al. Identification of novel markersof mouse fetal ovary development [J]. PLoS One,2012,7(7): e41683.
[39] Somfai, T., Imai, K., Kaneda, M., et al. The effect of ovary storage and in vitromaturation on mRNA levels in bovine oocytes; a possible impact of maternalATP1A1on blastocyst development in slaughterhouse-derived oocytes [J]. JReprod Dev,2011,57(6):723-730.
[40] Stansfield, F. J., Nothling, J. O., Allen, W. R. Growth and development of theovary and small follicle pool from mid fetal life to pre-puberty in the Africanelephant (Loxodonta africana)[J]. BMC Vet Res,2012,8:119.
[41] Sopher, A. B., Gerken, A. T., Blaner, W. S., et al. Metabolic manifestations ofpolycystic ovary syndrome in nonobese adolescents: retinol-binding protein4andectopic fat deposition [J]. Fertil Steril,2012,97(4):1009-1015.
[42]Pellatt L, Rice S, Di laver N, Hes hri A, Galea R, Brinca t M, et al. Anti-mullerianhormone reduces follicle se nsitivity to follicle-stim ulating horm one in humangranu losa cells [J]. Fertil Steril,2011;96:1246–1251.
[43] Ott, J., Wattar, L., Kurz, C., et al."Parameters for calcium metabolism in womenwith polycystic ovary syndrome who undergo clomiphene citrate stimulation: aprospective cohort study [J]. Eur J Endocrinol,2012,166(5):897-902.
[44] Wang, C., Roy, S. K. Expression of bone morphogenetic protein receptor (BMPR)during perinatal ovary development and primordial follicle formation in thehamster: possible regulation by FSH[J]. Endocrinology,2009,150(4):1886-1896.
[45]Webber LJ, Stubbs SA, Stark J, Margara RA, Trew GH, Lavery SA, et al.Prolonged survival in culture of preantr al follicles from polycystic ovaries [J]. JClin Endocr inol Metab,2007;92:1975–1978.
[46]Gras, S., Georg, B., Jorgensen, H. L., Fahrenkrug, J. Expression of the clockgenes Per1and Bmal1during follicle development in the rat ovary. Effects ofgonadotropin stimulation and hypophysectomy [J]. Cell Tissue Res,2012,350(3):539-548.
[47] Kuwabara, Y., Katayama, A., Igarashi, T., et al. Rapid and transient upregulationof CCL11(eotaxin-1) in mouse ovary during terminal stages of folliculardevelopment [J]. Am J Reprod Immunol,2012,67(5):358-368.
[48] Garcia-Ortiz, J. E., Pelosi, E., Omari, S., et al. Foxl2functions in sexdetermination and histogenesis throughout mouse ovary development [J]. BMCDev Biol,2009,9:36.
[49]Pisarska MD, Barlow D, Huo FT. Minire view: Roles of the fork headtranscription fact or FOXL2in granulosa cell biology and pathology [J].Endocrinology,2011,152:1199-1208.
[50] Pisarska MD, Kuo FT, Tan g D, Zarrini P, Khan S, Ketefian A. Expression offorkhead transcription factors in human granulosa cells [J]. Fertil Steril,2009,91:1392–1394.
[51]Richards JS, Sha rma SC, Falender AE, Lo YH. Expr ession of FKHR, FKHRL1and AFX genes in the rodent ovar y: evidence for regulation by IGF-I, estrogenand the gonadotropins [J]. Mol Endocr inol,2002,16:580–599.
[52] Liu Z, Castrillon DH, Zhou W, Richards JS. FOXO1/3depletion in granulosecells alters follicle growth, death and regulation of pituitary FSH [J]. MolEndocrinol,2013,27:238–252.
[53]Strauss JF, Williams CJ. The ovarian life cycle [M]. In: Strauss JF, Barbieri RL,editors. Yen and Jaffe's reproductive endocrinology: physiology, patho-physiology,and clinical management.6th ed. Philadelphia: Saunders Elsevier,2009:155–190.
[54]Boyer A, Lapoin te E, Zheng X, Cowan RG, Quir k SM, DeMayo FJ, et al. WNT4is required for normal ovarian follicle development and female fertility [J].FASEB J,2010,24:3010–3025.
[55]Boyer A, Goff AK, Boerb oom D. WNT signaling in ovar ian follicle biology andtumorigenesis [J]. Trends Endocrinol Metab,2010,21:25–32.
[56]Fortes, P., Salvador, G., Consoli, F. L. Ovary development and maturation inNezara viridula (L.)(Hemiptera: Pentatomidae)[J]. Neotrop Entomol,2011,40(1):89-96.
[57]Vilmann, L. S., Thisted, E., Baker, J. L., Holm, J. C. Development of obesity andpolycystic ovary syndrome in adolescents [J]. Horm Res Paediatr,2012,78(5-6):269-278.
[58]Gonzalez, F., Kirwan, J. P., Rote, N. S., Minium, J. Elevated circulating levels oftissue factor in polycystic ovary syndrome [J]. Clin Appl Thromb Hemost,2013,19(1):66-72.
[59]Legro, R. S., Kunselman, A. R., Brzyski, R. G., et al. The Pregnancy in PolycysticOvary Syndrome II (PPCOS II) trial: rationale and design of a double-blindrandomized trial of clomiphene citrate and letrozole for the treatment of infertilityin women with polycystic ovary syndrome [J]. Contemp Clin Trials,2012,33(3):470-481.
[60]Aleyasin, A., Aghahoseini, M., Mokhtar, S., Fallahi, P. Anti-mullerian hormone asa predictive factor in assisted reproductive technique of polycystic ovarysyndrome patients [J]. Acta Med Iran,2011,49(11):715-720.
[61]Mashiach, R., Amit, A., Hasson, J., et al. Follicular fluid levels of anti-Mullerianhormone as a predictor of oocyte maturation, fertilization rate, and embryonicdevelopment in patients with polycystic ovary syndrome [J]. Fertil Steril,2010,93(7):2299-2302.
[62]Kawai, T., Mihara, T., Kawashima, I., et al. Endogenous acetaldehyde toxicityduring antral follicular development in the mouse ovary [J]. Reprod Toxicol,2012,33(3):322-330.
[63]McGee WK, Bishop CV, Bahar A, Pohl CR, Ch ang RJ, Marshall JC, et al.Elevated androgens during puberty in female rhesus monkeys lead to increasedneuronal drive to the reproductive axis: a possible component of polycystic ovarysyndrome [J]. Hum Reprod,2012,27:531-540.
[64]Roland AV, Moenter SM. Prenatal andro genization of female mice programs anincrease infiring activity of gonadotropin-releasing hormone (GnRH) neuronsthat is reversed by metformin treatment in adulthood [J]. Endocrinology,2011,152:618-628.
[65]Garverick, H. A., Juengel, J. L., Smith, P., et al. Development of the ovary andontongeny of mRNA and protein for P450aromatase(arom) and estrogenreceptors (ER) alpha and beta during early fetal life in cattle [J]. Anim Reprod Sci117(1-2):24-33.
[66]Kenigsberg S, Bentov Y, Chalifa-Caspi V, et al. Gene expression microarrayprofiles of cumulus cells in lean and overweight-obese polycystic ovarysyndrome patients [J]. Mol Hum Reprod,2009,15:89-103.
[67]El-Khairi, R., Parnaik, R., Duncan, A. J., et al. Analysis of LIN28A in earlyhuman ovary development and as a candidate gene for primary ovarianinsufficiency [J]. Mol Cell Endocrinol,2012,351(2):264-268.
[68]Da Silva-Buttkus, P., Jayasooriya, G. S., Mora, J. M., et al. Effect of cell shapeand packing density on granulosa cell proliferation and formation of multiplelayers during early follicle development in the ovary [J]. J Cell Sci,2008,121(Pt23):3890-3900.
[69]Zeleznik AJ, Little-Ihrig L, Ramas awamy S. Administrat ion of dihydrotestosterone to rhesus monkeys inhibits gonadotropin-stimulated ovariansteroidogenesis [J]. J Cl in Endocrinol Metab,2004:89:860–866.
[70]Pradeep PK, Li X, Peegel H, Menon KM. Dihydrot estosterone inhibits granulosacell proliferation by decreasing the cyclin D2mRNA expression and cell cyclearrest at G1phase [J]. Endocrinology,2002,143:2930–935.
[71]Borisov, O. V., Field, M., Ling, V. T., Harris, R. J. Characterization ofoligosaccharides in recombinant tissue plasminogen activator produced inChinese hamster ovary cells: two decades of analytical technology development[J]. Anal Chem,2009,81(23):9744-9754.
[72]Duarte, A. B., Araujo, V. R., Chaves, R. N., et al. Insulin-like growth factor II(IGF-II) and follicle stimulating hormone (FSH) combinations can improve the invitro development of grown oocytes enclosed in caprine preantral follicles [J].Growth Horm IGF Res,2013,23(1-2):37-44.
[73]Ichikawa, C., Izawa, T., Juniantito, V., et al. Rat hair follicle-constituting cellslabeled by a newly-developed somatic stem cell-recognizing antibody: a possiblemarker of hair follicle development [J]. Histol Histopathol,2013,28(2):257-268.
[74]Frota, I. M., Leitao, C. C., Costa, J. J., et al. Levels of BMP-6mRNA in goatovarian follicles and in vitro effects of BMP-6on secondary follicle development[J]. Zygote,2011,1-9.
[75]Dumesic DA, Lesnick TG, Stassart JP, Ball GD, Wong A, Abbott DH.Intrafollicular antimullerian hormone levels predict follicle responsiveness tofollicle-stimulating hormone (FSH) in normoandrogenic ovulatory womenundergoing gonadotropin releasing-hormone analog/recombinant human FSHtherapy for in vitro fertilization and embryo transfer [J]. Fertil Steril,2009,92:217-221.
[76]Palma, G. A., Arganaraz, M. E., Barrera, A. D., et al. Biology and biotechnologyof follicle development [J]. Scientific World Journal,2012:938138.
[77]Dilaver NM, Goes D, Rice S, Mason HD. Anti-mullerian hormone may contributeto anovulation in PCOS via inhibition of human granulosa cell growth [A].Presented at the94th Annual Meeting of the Endocr ine Society [C]; June23–26,2012; Houston, TX; abstract: MON-18.
[78]Catteau-Jonard S, Jamin SP, Leclerc A, Gonzal" es J, Dewa illy D, di Clemente N.Anti-mullerian hormone, its receptor, FSH receptor, and androgen receptor genesare over expressed by granulosa cells from stimulated follicles in women withpolycystic ovary syndrome [J]. J Clin Endocrinol Metab,2008,93:4456–4461.
[79]Panidis D, Kats ikis I, Karkana ki A, Piouk a A, Arm eni AK, Ge orgopoulos NA.Serum anti-mullerian hormone (AMH) levels are differentially modulated by bothserum gonadotropins and not only by serum follicle stimulating hormone (FSH)levels [J]. Med Hypotheses,2011,77:649–653.
[80]Thomson RL, B uckley JD, Moran LJ, Noak es M, Clifton PM, Norman RJ,Brinkworth GD. The effect of weight loss on anti-mullerian hormone levels inoverweight and obese women with polycystic ovary syndrome and reproductiveimpairment [J]. Hum Reprod,2009,24:1976-1981.
[81]Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzo ne A, Guido M. Themetabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome [J].J Clin Endocrinol Metab,2011,96: E821–E824.
[82]Knight PG, Glister C. Potential local regulatory functions of inhibins, activins andfollistatin in the ovary [J]. Reproduction,2001,121:503-512.
[83]Gold, E., Marino, F. E., Harrison, C., et al. Activin-beta(c) reduces reproductivetumour progression and abolishes cancer-associated cachexia in inhibin-deficientmice [J]. J Pathol,2013,229(4):599-607.
[84]Winnall, W. R., Wu, H., Sarraj, M. A., et al. Expression patterns of activin, inhibinand follistatin variants in the adult male mouse reproductive tract suggestimportant roles in the epididymis and vas deferens [J]. Reprod Fertil Dev25(3):570-580.
[85]Lee, Y., Jung, J., Cho, K. J., et al. Increased SCF/c-kit by hypoxia promotesautophagy of human placental chorionic plate-derived mesenchymal stem cellsvia regulating the phosphorylation of mTOR. J Cell Biochem [J],2013,114(1):79-88.
[86]Jin, Q. H., Shen, H. X., Wang, H., et al. Curcumin improves expression ofSCF/c-kit through attenuating oxidative stress and NF-kappaB activation ingastric tissues of diabetic gastroparesis rats [J]. Diabetol Metab Syndr,2013,5(1):12.
[87]Li, S., Park, H., Trempus, C. S., et al. A keratin15containing stem cell populationfrom the hair follicle contributes to squamous papilloma development in themouse [J]. Mol Carcinog,2012, doi:10.1002/mc.21896.[Epub ahead of print]
[88]Phelan, N., O'Connor, A., Kyaw Tun, T., et al. Leucocytosis in women withpolycystic ovary syndrome (PCOS) is incompletely explained by obesity andinsulin resistance [J]. Clin Endocrinol (Oxf),2013,78(1):107-113.
[89]Flannery, C. A., Rackow, B., Cong, X., et al. Polycystic ovary syndrome inadolescence: impaired glucose tolerance occurs across the spectrum of BMI [J].Pediatr Diabetes,2013,14(1):42-49.
[90]Yildiz, B. O., Bozdag, G., Yapici, Z., et al. Prevalence, phenotype andcardiometabolic risk of polycystic ovary syndrome under different diagnosticcriteria [J]. Hum Reprod,2012,27(10):3067-3073.
[91]Sir-Petermann T, Codner E, Perez V, et al. Metabolic and reproductive featuresbefore and during puberty in daughters of women with polycystic ovarysyndrome [J]. J Clin Endocrinol Metab,2009,94:1923-1930.